<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<addis-data xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://drugis.org/files/addis-6.xsd">
    <units>
        <unit name="gram" symbol="g"/>
        <unit name="liter" symbol="l"/>
    </units>
    <indications>
        <indication code="38341003" name="Hypertensive disorder"/>
    </indications>
    <drugs>
        <drug name="Azilsartan" atcCode="C09CA09"/>
        <drug name="Chlortalidone" atcCode="C03BA04"/>
        <drug name="Hydrochlorothiazide" atcCode="C03AA03"/>
        <drug name="Olmesartan" atcCode="C09CA08"/>
        <drug name="Placebo" atcCode="Placebo"/>
        <drug name="Ramipril" atcCode="C09AA05"/>
        <drug name="Valsartan" atcCode="C09CA03"/>
    </drugs>
    <treatmentCategorizations>
        <treatmentCategorization drug="Azilsartan" name="20/40/80">
            <unit scaleModifier="MILLI" perTime="P1D">
                <unit name="gram"/>
            </unit>
            <category name="20"/>
            <category name="40"/>
            <category name="80"/>
            <decisionTree>
                <rootNode>
                    <typeEdge matchType="FixedDose">
                        <choiceNode objectType="FixedDose" property="quantity">
                            <rangeEdge rangeLowerBound="0.0" isRangeLowerBoundOpen="false" rangeUpperBound="20.0" isRangeUpperBoundOpen="false">
<leafNode>
    <category name="20"/>
</leafNode>
                            </rangeEdge>
                            <rangeEdge rangeLowerBound="20.0" isRangeLowerBoundOpen="true" rangeUpperBound="40.0" isRangeUpperBoundOpen="false">
<leafNode>
    <category name="40"/>
</leafNode>
                            </rangeEdge>
                            <rangeEdge rangeLowerBound="40.0" isRangeLowerBoundOpen="true" rangeUpperBound="80.0" isRangeUpperBoundOpen="false">
<leafNode>
    <category name="80"/>
</leafNode>
                            </rangeEdge>
                            <rangeEdge rangeLowerBound="80.0" isRangeLowerBoundOpen="true" rangeUpperBound="INF" isRangeUpperBoundOpen="true">
<leafNode/>
                            </rangeEdge>
                        </choiceNode>
                    </typeEdge>
                    <typeEdge matchType="FlexibleDose">
                        <choiceNode objectType="FlexibleDose" property="maxDose">
                            <rangeEdge rangeLowerBound="0.0" isRangeLowerBoundOpen="false" rangeUpperBound="20.0" isRangeUpperBoundOpen="false">
<leafNode>
    <category name="20"/>
</leafNode>
                            </rangeEdge>
                            <rangeEdge rangeLowerBound="20.0" isRangeLowerBoundOpen="true" rangeUpperBound="40.0" isRangeUpperBoundOpen="false">
<leafNode>
    <category name="40"/>
</leafNode>
                            </rangeEdge>
                            <rangeEdge rangeLowerBound="40.0" isRangeLowerBoundOpen="true" rangeUpperBound="80.0" isRangeUpperBoundOpen="false">
<leafNode>
    <category name="80"/>
</leafNode>
                            </rangeEdge>
                            <rangeEdge rangeLowerBound="80.0" isRangeLowerBoundOpen="true" rangeUpperBound="INF" isRangeUpperBoundOpen="true">
<leafNode/>
                            </rangeEdge>
                        </choiceNode>
                    </typeEdge>
                    <typeEdge matchType="UnknownDose">
                        <leafNode/>
                    </typeEdge>
                </rootNode>
            </decisionTree>
        </treatmentCategorization>
    </treatmentCategorizations>
    <endpoints>
        <endpoint name="DBP 12-hour mean" description="Change from baseline in the 12-hour mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP 24-hour mean" description="Change from baseline in the 24-hour mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP daytime mean" description="Change from baseline in daytime (6am - 10pm) mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP mean trough (clinic, sitting)" description="Change from baseline in mean trough clinic sitting diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP nighttime mean" description="Change from baseline in the nighttime (12am - 6am) mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="DBP response (clinic)" description="Participants who achieve a clinic diastolic blood pressure response, defined as &lt; 90 mmHg and/or reduction from baseline at least 10 mmHg" direction="HIGHER_IS_BETTER">
            <rate/>
        </endpoint>
        <endpoint name="DBP trough mean" description="Change from baseline in the trough (22-24hr) mean diastolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP 12-hour mean" description="Change from baseline in the 12-hour mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP 24-hour mean" description="Change from baseline in the 24-hour mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP and DBP response (clinic)" description="Participants who achieve both clinic SBP and clinic DBP response" direction="HIGHER_IS_BETTER">
            <rate/>
        </endpoint>
        <endpoint name="SBP daytime mean" description="Change from baseline in daytime (6am - 10pm) mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP mean trough (clinic, sitting)" description="Change from baseline in mean trough clinic sitting systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP nighttime mean" description="Change from baseline in nighttime (12am - 6am) mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
        <endpoint name="SBP response (clinic)" description="Participants who achieve a clinic systolic blood pressure response, defined as &lt; 140 mmHg and/or reduction frome baseline at least 20 mmHg" direction="HIGHER_IS_BETTER">
            <rate/>
        </endpoint>
        <endpoint name="SBP trough mean" description="Change from baseline in the trough (22-24hr) mean systolic blood pressure" direction="LOWER_IS_BETTER">
            <continuous unitOfMeasurement="mmHg"/>
        </endpoint>
    </endpoints>
    <adverseEvents>
        <adverseEvent name="Abdominal adhesions" description="Abdominal adhesions (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Acute coronary syndrome" description="Acute coronary syndrome (Cardiac disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Angina pectoris" description="Angina pectoris (Cardiac disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Angioedema" description="Angioedema (Skin and subcutaneous tissue disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Ankle fracture" description="Ankle fracture (Injury, poisoning and procedural complications)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Appendicitis" description="Appendicitis (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Asthma" description="Asthma (Respiratory, thoracic and mediastinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Atrial fibrillation" description="Atrial fibrillation (Cardiac disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Blood creatinine increased" description="Blood creatinine increased (Investigations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Blood creatinine increased (non-serious)" description="Blood creatinine increased (Investigations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Blood pressure increased" description="Blood pressure increased (Investigations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Breast cancer" description="Breast cancer (Neoplasms benign, malignant and unspecified (incl cysts and polyps))" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cardiac arrest" description="Cardiac arrest (Cardiac disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cataract" description="Cataract (Eye disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cellulitis" description="Cellulitis (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cerebral haemorrhage" description="Cerebral haemorrhage (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cerebral infarction" description="Cerebral infarction (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cerebral ischaemia" description="Cerebral ischaemia (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Chest pain" description="Chest pain (General disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cholecystitis" description="Cholecystitis (Hepatobiliary disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cholecystitis chronic" description="Cholecystitis chronic (Hepatobiliary disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cholelithiasis" description="Cholelithiasis (Hepatobiliary disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Coronary artery disease" description="Coronary artery disease (Cardiac disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Cough" description="Cough (Respiratory, thoracic and mediastinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Deep vein thrombosis" description="Deep vein thrombosis (Vascular disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Dehydration" description="Dehydration (Metabolism and nutrition disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Diabetic ketoacidosis" description="Diabetic ketoacidosis (Metabolism and nutrition disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Diarrhoea" description="Diarrhoea (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Diastolic dysfunction" description="Diastolic dysfunction (Cardiac disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Diverticulitis" description="Diverticulitis (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Dizziness" description="Dizziness (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Dysfunctional uterine bleeding" description="Dysfunctional uterine bleeding (Reproductive system and breast disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Dyslipidemia" description="Dyslipidemia (Metabolism and nutrition disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Epigastric discomfort" description="Epigastric discomfort (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Epilepsy" description="Epilepsy (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Eye irritation" description="Eye irritation (Eye disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Fall" description="Fall (Injury, poisoning and procedural complications)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Gastroenteritis" description="Gastroenteritis (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Gastrointestinal haemorrhage" description="Gastrointestinal haemorrhage (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Generalised oedema" description="Generalised oedema (General disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Grand mal convulsion" description="Grand mal convulsion (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Headache" description="Headache (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Heat exhaustion" description="Heat exhaustion (Injury, poisoning and procedural complications)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Hepatitis C" description="Hepatitis C (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Hydrocele" description="Hydrocele (Congenital, familial and genetic disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Hyperkalaemia" description="Hyperkalaemia (Metabolism and nutrition disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Infected bites" description="Infected bites (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Inguinal hernia" description="Inguinal hernia (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Intentional overdose" description="Intentional overdose (Injury, poisoning and procedural complications)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Ischaemia" description="Ischaemia (Vascular disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Ischaemic stroke" description="Ischaemic stroke (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Laryngeal oedema" description="Laryngeal oedema (Respiratory, thoracic and mediastinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Lower respiratory tract infection" description="Lower respiratory tract infection (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Lung neoplasm malignant" description="Lung neoplasm malignant (Neoplasms benign, malignant and unspecified (incl cysts and polyps))" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Myelodysplastic syndrome" description="Myelodysplastic syndrome (Neoplasms benign, malignant and unspecified (incl cysts and polyps))" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Myocardial infarction" description="Myocardial infarction (Cardiac disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Nasopharyngitis" description="Nasopharyngitis (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Nausea" description="Nausea (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Non-SAE" description="Non-serious adverse events (total)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Pancreatitis" description="Pancreatitis (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Partial seizures" description="Partial seizures (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Pneumonia" description="Pneumonia (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Pulmonary embolism" description="Pulmonary embolism (Respiratory, thoracic and mediastinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Renal cancer" description="Renal cancer (Neoplasms benign, malignant and unspecified (incl cysts and polyps))" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Retinal detachment" description="Retinal detachment (Eye disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Road traffic accident" description="Road traffic accident (Injury, poisoning and procedural complications)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="SAE" description="Serious adverse events" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Salivary gland calculus" description="Salivary gland calculus (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Shock" description="Shock (Vascular disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Sleep apnoea syndrome" description="Sleep apnoea syndrome (Respiratory, thoracic and mediastinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Status asthmaticus" description="Status asthmaticus (Respiratory, thoracic and mediastinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Subdural haematoma" description="Subdural haematoma (Injury, poisoning and procedural complications)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Syncope" description="Syncope (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Systemic inflammatory response syndrome" description="Systemic inflammatory response syndrome (General disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Transient ischaemic attack" description="Transient ischaemic attack (Nervous system disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Troponin increased" description="Troponin increased (Investigations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Upper respiratory tract infection" description="Upper respiratory tract infection (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Urosepsis" description="Urosepsis (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Viral infection" description="Viral infection (Infections and infestations)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
        <adverseEvent name="Vomiting" description="Vomiting (Gastrointestinal disorders)" direction="LOWER_IS_BETTER">
            <rate/>
        </adverseEvent>
    </adverseEvents>
    <populationCharacteristics>
        <populationCharacteristic name="Age" description="Age in years">
            <continuous unitOfMeasurement="years"/>
        </populationCharacteristic>
        <populationCharacteristic name="Age (cut-off 45, 65)" description="Age in years">
            <categorical>
                <category>&lt; 45</category>
                <category>45-64</category>
                <category>&gt; 64</category>
            </categorical>
        </populationCharacteristic>
        <populationCharacteristic name="BMI" description="Body Mass Index">
            <continuous unitOfMeasurement="kg/m^2"/>
        </populationCharacteristic>
        <populationCharacteristic name="Chronic Kidney Disease" description="Chronic Kidney Disease (CKD) Status">
            <rate/>
        </populationCharacteristic>
        <populationCharacteristic name="Diabetes" description="Diabetes Status">
            <rate/>
        </populationCharacteristic>
        <populationCharacteristic name="Ethnicity" description="Ethnicity (NIH/OMB)">
            <categorical>
                <category>Hispanic or Latino</category>
                <category>Not Hispanic or Latino</category>
                <category>Unknown or Not Reported</category>
            </categorical>
        </populationCharacteristic>
        <populationCharacteristic name="Gender" description="Gender (male, female)">
            <categorical>
                <category>Female</category>
                <category>Male</category>
            </categorical>
        </populationCharacteristic>
        <populationCharacteristic name="Height" description="Body height in cm">
            <continuous unitOfMeasurement="cm"/>
        </populationCharacteristic>
        <populationCharacteristic name="Race" description="Race (NIH/OMB)">
            <categorical>
                <category>American Indian or Alaska Native</category>
                <category>Asian</category>
                <category>Native Hawaiian or Other Pacific Islander</category>
                <category>Black or African American</category>
                <category>White</category>
                <category>More than one race</category>
                <category>Unknown or Not Reported</category>
            </categorical>
        </populationCharacteristic>
        <populationCharacteristic name="Region of Enrollment" description="Region of Enrollment">
            <categorical>
                <category>United States</category>
                <category>Mexico</category>
                <category>Chile</category>
                <category>Argentina</category>
            </categorical>
        </populationCharacteristic>
        <populationCharacteristic name="Weight" description="Body weight in kg">
            <continuous unitOfMeasurement="kg"/>
        </populationCharacteristic>
        <populationCharacteristic name="eGFR category" description="Estimated Glomerular Filtration Rate Category">
            <categorical>
                <category>Moderate impairment</category>
                <category>Mild impairment</category>
                <category>Normal</category>
            </categorical>
        </populationCharacteristic>
    </populationCharacteristics>
    <studies>
        <study name="TAK491-008 / NCT00696241">
            <indication name="Hypertensive disorder">
                <notes>
                    <note source="CLINICALTRIALS">Hypertension</note>
                </notes>
            </indication>
            <characteristics>
                <title>
                    <value>Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension</value>
                    <notes>
                        <note source="CLINICALTRIALS">Brief title: Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Official title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension</note>
                    </notes>
                </title>
                <allocation>
                    <value>RANDOMIZED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </allocation>
                <blinding>
                    <value>DOUBLE_BLIND</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </blinding>
                <centers>
                    <value>85</value>
                    <notes>
                        <note source="CLINICALTRIALS">Birmingham, Alabama, United States
Huntsville, Alabama, United States
Mesa, Arizona, United States
Phoenix, Arizona, United States
Tempe, Arizona, United States
Little Rock, Arkansas, United States
Tempe, Arkansas, United States
Beverly Hills, California, United States
Carmichael, California, United States
Fountain Valley, California, United States
Long Beach, California, United States
Los Gatos, California, United States
Orangevale, California, United States
Sacramento, California, United States
Santa Ana, California, United States
Spring Valley, California, United States
Tustin, California, United States
Westlake Village, California, United States
Colorado Springs, Colorado, United States
Farmington, Connecticut, United States
Hollywood, Florida, United States
Jacksonville, Florida, United States
Jupiter, Florida, United States
Melbourne, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
Ocala, Florida, United States
Pembroke Pines, Florida, United States
Sarasota, Florida, United States
St. Petersburg, Florida, United States
Augusta, Georgia, United States
Lawrenceville, Georgia, United States
Chicago, Illinois, United States
Melrose Park, Illinois, United States
Naperville, Illinois, United States
Round Lake Beach, Illinois, United States
Valparaiso, Indiana, United States
Wichita, Kansas, United States
Erlanger, Kentucky, United States
Lexington, Kentucky, United States
Auburn, Maine, United States
West Yarmouth, Massachusetts, United States
Benzonia, Michigan, United States
Chelsea, Michigan, United States
Omaha, Nebraska, United States
Trenton, New Jersey, United States
Wildwood Crest, New Jersey, United States
Albuquerque, New Mexico, United States
Brooklyn, New York, United States
Orangevale, New York, United States
Rochester, New York, United States
Burlington, North Carolina, United States
Charlotte, North Carolina, United States
Raleigh, North Carolina, United States
Salisbury, North Carolina, United States
Statesville, North Carolina, United States
Wilmington, North Carolina, United States
Winston-Salem, North Carolina, United States
Kettering, Ohio, United States
Lyndhurst, Ohio, United States
Marion, Ohio, United States
Norman, Oklahoma, United States
Oklahoma City, Oklahoma, United States
Altoona, Pennsylvania, United States
Reading, Pennsylvania, United States
Mt. Pleasant, South Carolina, United States
Simpsonville, South Carolina, United States
Taylors, South Carolina, United States
Nashville, Tennessee, United States
New Tazewell, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
Lake Jackson, Texas, United States
North Richland Hills, Texas, United States
San Antonio, Texas, United States
Draper, Utah, United States
Burke, Virginia, United States
Norfolk, Virginia, United States
Tacoma, Washington, United States
Madison, Wisconsin, United States
Provincia de Buenos Aires, Argentina
Provincia de Cordoba, Argentina
Aguascalientes,, Mexico
Mexico DF, Mexico
San Luis Potosi, Mexico
</note>
                    </notes>
                </centers>
                <objective>
                    <value>The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil,once daily (QD), compared to placebo and olmesartan in participants with essentialhypertension.</value>
                    <notes>
                        <note source="CLINICALTRIALS">The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil,once daily (QD), compared to placebo and olmesartan in participants with essentialhypertension.</note>
                    </notes>
                </objective>
                <study_start>
                    <value>2007-06-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">June 2007</note>
                    </notes>
                </study_start>
                <study_end>
                    <value>2008-10-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">October 2008</note>
                    </notes>
                </study_end>
                <status>
                    <value>COMPLETED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Completed</note>
                    </notes>
                </status>
                <inclusion>
                    <value>1. Has essential hypertension (defined as sitting trough clinic systolic blood pressurebetween 150 and 180 mm Hg, inclusive at Day minus 1) and 24-hour mean systolic bloodpressure greater than or equal to 130 mm Hg and less than or equal to 170 mm Hg atDay 1).

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Clinical laboratory evaluations (including clinical chemistry, hematology, andcomplete urinalysis) within the reference range for the testing laboratory or theresults are deemed not clinically significant for inclusion into this study by theinvestigator.

4. The subject is willing to discontinue current antihypertensive medications at theScreening Day minus 21 visit. If the subject is on amlodipine prior to screening, thesubject is willing to discontinue this medication at Screening Day minus 28.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria

1. Has essential hypertension (defined as sitting trough clinic systolic blood pressurebetween 150 and 180 mm Hg, inclusive at Day minus 1) and 24-hour mean systolic bloodpressure greater than or equal to 130 mm Hg and less than or equal to 170 mm Hg atDay 1).

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Clinical laboratory evaluations (including clinical chemistry, hematology, andcomplete urinalysis) within the reference range for the testing laboratory or theresults are deemed not clinically significant for inclusion into this study by theinvestigator.

4. The subject is willing to discontinue current antihypertensive medications at theScreening Day minus 21 visit. If the subject is on amlodipine prior to screening, thesubject is willing to discontinue this medication at Screening Day minus 28.

Exclusion Criteria

1. Sitting trough clinic diastolic blood pressure greater than 114 mm Hg at Day minus 1.

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

4. Clinically significant cardiac conduction defects (eg, third degree atrioventricularblock, left bundle branch block, sick sinus syndrome, atrial fibrillation or atrialflutter).

5. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

6. Secondary hypertension of any etiology.

7. Is noncompliant (less than 70% or greater than 130%) with study medication duringPlacebo Run-In Period.

8. Severe renal dysfunction or disease (based on calculated creatinine clearance lessthan 30 mL/min/1.73 m2) at Screening.

9. Known or suspected unilateral or bilateral renal artery stenosis.

10. History of drug abuse (defined as illicit drug use) or a history of alcohol abuse(defined as regular or daily consumption of more than 2 alcoholic drinks per day)within the past 2 years.

11. History of cancer that has not been in remission for at least 5 years prior to thefirst dose of study drug. (This criterion does not apply to those subjects with basalcell or stage I squamous cell carcinoma of the skin).

12. Type 1 or poorly controlled type 2 diabetes mellitus (glycosylated hemoglobin greaterthan 8.0%) at Screening.

13. Alanine aminotransferase level greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

14. Hyperkalemia (defined as serum potassium greater than the upper limit of normal perthe central laboratory) at Screening.

15. Upper arm circumference less than 24 cm or greater than 42 cm.

16. Works night (3rd) shift (defined as 11 PM to 7 AM).

17. Currently participating in another investigational study or has participated in aninvestigational study within 30 days prior to Screening.

18. Any other serious disease or condition at Screening (or Randomization) that wouldcompromise subject safety, might affect life expectancy, or make it difficult tosuccessfully manage and follow the subject according to the protocol.

19. Randomized in a previous azilsartan medoxomil study.</note>
                    </notes>
                </inclusion>
                <exclusion>
                    <value>1. Sitting trough clinic diastolic blood pressure greater than 114 mm Hg at Day minus 1.

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

4. Clinically significant cardiac conduction defects (eg, third degree atrioventricularblock, left bundle branch block, sick sinus syndrome, atrial fibrillation or atrialflutter).

5. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

6. Secondary hypertension of any etiology.

7. Is noncompliant (less than 70% or greater than 130%) with study medication duringPlacebo Run-In Period.

8. Severe renal dysfunction or disease (based on calculated creatinine clearance lessthan 30 mL/min/1.73 m2) at Screening.

9. Known or suspected unilateral or bilateral renal artery stenosis.

10. History of drug abuse (defined as illicit drug use) or a history of alcohol abuse(defined as regular or daily consumption of more than 2 alcoholic drinks per day)within the past 2 years.

11. History of cancer that has not been in remission for at least 5 years prior to thefirst dose of study drug. (This criterion does not apply to those subjects with basalcell or stage I squamous cell carcinoma of the skin).

12. Type 1 or poorly controlled type 2 diabetes mellitus (glycosylated hemoglobin greaterthan 8.0%) at Screening.

13. Alanine aminotransferase level greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

14. Hyperkalemia (defined as serum potassium greater than the upper limit of normal perthe central laboratory) at Screening.

15. Upper arm circumference less than 24 cm or greater than 42 cm.

16. Works night (3rd) shift (defined as 11 PM to 7 AM).

17. Currently participating in another investigational study or has participated in aninvestigational study within 30 days prior to Screening.

18. Any other serious disease or condition at Screening (or Randomization) that wouldcompromise subject safety, might affect life expectancy, or make it difficult tosuccessfully manage and follow the subject according to the protocol.

19. Randomized in a previous azilsartan medoxomil study.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria

1. Has essential hypertension (defined as sitting trough clinic systolic blood pressurebetween 150 and 180 mm Hg, inclusive at Day minus 1) and 24-hour mean systolic bloodpressure greater than or equal to 130 mm Hg and less than or equal to 170 mm Hg atDay 1).

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Clinical laboratory evaluations (including clinical chemistry, hematology, andcomplete urinalysis) within the reference range for the testing laboratory or theresults are deemed not clinically significant for inclusion into this study by theinvestigator.

4. The subject is willing to discontinue current antihypertensive medications at theScreening Day minus 21 visit. If the subject is on amlodipine prior to screening, thesubject is willing to discontinue this medication at Screening Day minus 28.

Exclusion Criteria

1. Sitting trough clinic diastolic blood pressure greater than 114 mm Hg at Day minus 1.

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

4. Clinically significant cardiac conduction defects (eg, third degree atrioventricularblock, left bundle branch block, sick sinus syndrome, atrial fibrillation or atrialflutter).

5. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

6. Secondary hypertension of any etiology.

7. Is noncompliant (less than 70% or greater than 130%) with study medication duringPlacebo Run-In Period.

8. Severe renal dysfunction or disease (based on calculated creatinine clearance lessthan 30 mL/min/1.73 m2) at Screening.

9. Known or suspected unilateral or bilateral renal artery stenosis.

10. History of drug abuse (defined as illicit drug use) or a history of alcohol abuse(defined as regular or daily consumption of more than 2 alcoholic drinks per day)within the past 2 years.

11. History of cancer that has not been in remission for at least 5 years prior to thefirst dose of study drug. (This criterion does not apply to those subjects with basalcell or stage I squamous cell carcinoma of the skin).

12. Type 1 or poorly controlled type 2 diabetes mellitus (glycosylated hemoglobin greaterthan 8.0%) at Screening.

13. Alanine aminotransferase level greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

14. Hyperkalemia (defined as serum potassium greater than the upper limit of normal perthe central laboratory) at Screening.

15. Upper arm circumference less than 24 cm or greater than 42 cm.

16. Works night (3rd) shift (defined as 11 PM to 7 AM).

17. Currently participating in another investigational study or has participated in aninvestigational study within 30 days prior to Screening.

18. Any other serious disease or condition at Screening (or Randomization) that wouldcompromise subject safety, might affect life expectancy, or make it difficult tosuccessfully manage and follow the subject according to the protocol.

19. Randomized in a previous azilsartan medoxomil study.</note>
                    </notes>
                </exclusion>
                <references>
                    <pubMedId>21282560</pubMedId>
                    <pubMedId>21272195</pubMedId>
                </references>
                <source>
                    <value>CLINICALTRIALS</value>
                    <notes>
                        <note source="CLINICALTRIALS">http://clinicaltrials.gov/show/NCT00696241</note>
                    </notes>
                </source>
                <creation_date>
                    <value>2012-09-24</value>
                    <notes>
                        <note source="CLINICALTRIALS">Information obtained from ClinicalTrials.gov on September 20, 2012</note>
                    </notes>
                </creation_date>
            </characteristics>
            <studyOutcomeMeasures>
                <studyOutcomeMeasure id="endpoint-SBP 24-hour mean" primary="true">
                    <endpoint name="SBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="SBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure
Description: The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 24-hour mean" primary="false">
                    <endpoint name="DBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="DBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
Description: The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP daytime mean" primary="false">
                    <endpoint name="SBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP daytime mean" primary="false">
                    <endpoint name="DBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP nighttime mean" primary="false">
                    <endpoint name="SBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP nighttime mean" primary="false">
                    <endpoint name="DBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP 12-hour mean" primary="false">
                    <endpoint name="SBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
Description: The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 12-hour mean" primary="false">
                    <endpoint name="DBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
Description: The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP trough mean" primary="false">
                    <endpoint name="SBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP trough mean" primary="false">
                    <endpoint name="DBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP response (clinic)" primary="false">
                    <endpoint name="SBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as &lt; 140 mm Hg and/or Reduction From Baseline  20 mm Hg
Description: Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP response (clinic)" primary="false">
                    <endpoint name="DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as &lt; 90 mm Hg and/or Reduction From Baseline  10 mm Hg
Description: Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)" primary="false">
                    <endpoint name="SBP and DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
Description: Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-SAE" primary="false">
                    <adverseEvent name="SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, serious adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation" primary="false">
                    <adverseEvent name="Atrial fibrillation"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Atrial fibrillation (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Coronary artery disease" primary="false">
                    <adverseEvent name="Coronary artery disease"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Coronary artery disease (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Myocardial infarction" primary="false">
                    <adverseEvent name="Myocardial infarction"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Myocardial infarction (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage" primary="false">
                    <adverseEvent name="Gastrointestinal haemorrhage"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gastrointestinal haemorrhage (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Inguinal hernia" primary="false">
                    <adverseEvent name="Inguinal hernia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Inguinal hernia (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Chest pain" primary="false">
                    <adverseEvent name="Chest pain"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Chest pain (General disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic" primary="false">
                    <adverseEvent name="Cholecystitis chronic"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cholecystitis chronic (Hepatobiliary disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cellulitis" primary="false">
                    <adverseEvent name="Cellulitis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cellulitis (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection" primary="false">
                    <adverseEvent name="Lower respiratory tract infection"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Lower respiratory tract infection (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Pneumonia" primary="false">
                    <adverseEvent name="Pneumonia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Pneumonia (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome" primary="false">
                    <adverseEvent name="Myelodysplastic syndrome"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Myelodysplastic syndrome (Neoplasms benign, malignant and unspecified (incl cysts and polyps))</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Epilepsy" primary="false">
                    <adverseEvent name="Epilepsy"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Epilepsy (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke" primary="false">
                    <adverseEvent name="Ischaemic stroke"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Ischaemic stroke (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack" primary="false">
                    <adverseEvent name="Transient ischaemic attack"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Transient ischaemic attack (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Status asthmaticus" primary="false">
                    <adverseEvent name="Status asthmaticus"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Status asthmaticus (Respiratory, thoracic and mediastinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Ischaemia" primary="false">
                    <adverseEvent name="Ischaemia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Ischaemia (Vascular disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Shock" primary="false">
                    <adverseEvent name="Shock"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Shock (Vascular disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Non-SAE" primary="false">
                    <adverseEvent name="Non-SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, other adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Dyslipidemia" primary="false">
                    <adverseEvent name="Dyslipidemia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Dyslipidemia (Metabolism and nutrition disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Headache" primary="false">
                    <adverseEvent name="Headache"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Headache (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)" primary="false">
                    <populationCharacteristic name="Age (cut-off 45, 65)"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Age
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Gender" primary="false">
                    <populationCharacteristic name="Gender"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gender
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
            </studyOutcomeMeasures>
            <arms>
                <arm name="Azilsartan Medoxomil 20 mg QD" size="283">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 20 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil and olmesartan
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Azilsartan Medoxomil 40 mg QD" size="283">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 40 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil and olmesartan
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Azilsartan Medoxomil 80 mg QD" size="285">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 80 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil and olmesartan
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Olmesartan 40 mg QD" size="282">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Olmesartan 40 mg QD
Arm Type: Active Comparator

Intervention Name: Olmesartan
Intervention Type: Drug
Intervention Description: Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Placebo QD" size="142">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Placebo QD
Arm Type: Placebo Comparator

Intervention Name: Placebo
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.</note>
                    </notes>
                </arm>
            </arms>
            <measurements>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-7.72" sampleSize="241" stdDev="8.057046667358954"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.63" sampleSize="244" stdDev="8.060177665535667"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.88" sampleSize="243" stdDev="8.059232407617987"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.86" sampleSize="250" stdDev="8.063808033429368"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.47" sampleSize="120" stdDev="8.062476046476045"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-7.47" sampleSize="241" stdDev="7.110072010887091"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.38" sampleSize="244" stdDev="7.107327205075055"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.61" sampleSize="243" stdDev="7.108336514262673"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.74" sampleSize="250" stdDev="7.099313347078011"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.69" sampleSize="120" stdDev="7.109438796417057"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-7.71" sampleSize="241" stdDev="7.606845601167412"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.43" sampleSize="244" stdDev="7.60718318433308"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.87" sampleSize="243" stdDev="7.607167146842509"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.82" sampleSize="250" stdDev="7.605277772704952"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.59" sampleSize="120" stdDev="7.613343549321809"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-6.82" sampleSize="274" stdDev="8.855825766127065"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-6.86" sampleSize="276" stdDev="8.854861037870668"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.42" sampleSize="279" stdDev="8.852745336899735"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-6.91" sampleSize="280" stdDev="8.85186308073052"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="0.21" sampleSize="140" stdDev="8.862287515083224"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-6.98" sampleSize="241" stdDev="8.274385113106593"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.9" sampleSize="244" stdDev="8.278864656461053"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-7.79" sampleSize="243" stdDev="8.277470809371666"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.62" sampleSize="250" stdDev="8.269356081340312"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.96" sampleSize="120" stdDev="8.270610618328009"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="185" sampleSize="274"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="196" sampleSize="276"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="205" sampleSize="279"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="208" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="67" sampleSize="140"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-7.96" sampleSize="241" stdDev="9.531843263503655"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.93" sampleSize="244" stdDev="9.528504604606118"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.68" sampleSize="242" stdDev="9.520485701895675"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.56" sampleSize="250" stdDev="9.534267145407663"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.12" sampleSize="120" stdDev="9.530372500589891"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-12.72" sampleSize="241" stdDev="12.34171888352672"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-14.05" sampleSize="244" stdDev="12.340194487932514"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-15.18" sampleSize="243" stdDev="12.330469699082839"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-13.07" sampleSize="250" stdDev="12.33288287465668"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.36" sampleSize="120" stdDev="12.33471199501634"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-12.15" sampleSize="241" stdDev="11.006639859648356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-13.48" sampleSize="244" stdDev="10.996831543676569"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-14.62" sampleSize="243" stdDev="11.005450831292647"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-12.56" sampleSize="250" stdDev="11.00472625738596"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.4" sampleSize="120" stdDev="10.998268954703736"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="117" sampleSize="274"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="125" sampleSize="276"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="145" sampleSize="279"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="133" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="20" sampleSize="140"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-12.57" sampleSize="241" stdDev="11.658655196891278"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-13.75" sampleSize="244" stdDev="11.652892516452727"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-14.96" sampleSize="243" stdDev="11.644577579285562"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-12.73" sampleSize="250" stdDev="11.652993177720477"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.54" sampleSize="120" stdDev="11.655536023709935"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-14.28" sampleSize="274" stdDev="15.824615761527987"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-14.47" sampleSize="276" stdDev="15.815811834996014"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-17.58" sampleSize="279" stdDev="15.818018554800092"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-14.87" sampleSize="280" stdDev="15.812874501494028"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-2.06" sampleSize="140" stdDev="15.819597340008373"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-11.1" sampleSize="241" stdDev="12.12438043777908"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.39" sampleSize="244" stdDev="12.105886997655315"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-13.35" sampleSize="243" stdDev="12.11223129732916"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-12.13" sampleSize="250" stdDev="12.111523438444893"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.97" sampleSize="120" stdDev="12.104668520864172"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="131" sampleSize="274"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="139" sampleSize="276"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="158" sampleSize="279"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="149" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="24" sampleSize="140"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <continuousMeasurement mean="-12.15" sampleSize="241" stdDev="13.412886937568661"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.39" sampleSize="244" stdDev="13.402388443855818"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-13.42" sampleSize="242" stdDev="13.409572998421687"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-11.1" sampleSize="250" stdDev="13.408057279113928"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.21" sampleSize="120" stdDev="13.408248207726466"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="1" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis chronic"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="1" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="10" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="11" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="16" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="10" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dyslipidemia"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="3" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="13" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="9" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="16" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="9" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="10" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Inguinal hernia"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemia"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="1" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lower respiratory tract infection"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myelodysplastic syndrome"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Myocardial infarction"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="23" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="19" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="32" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="18" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="13" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="8" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="2" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="3" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Status asthmaticus"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="281"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="282"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Transient ischaemic attack"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="142"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="141"/>
                        <category name="45-64" rate="758"/>
                        <category name="&gt; 64" rate="376"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="32"/>
                        <category name="45-64" rate="173"/>
                        <category name="&gt; 64" rate="78"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="29"/>
                        <category name="45-64" rate="187"/>
                        <category name="&gt; 64" rate="67"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="37"/>
                        <category name="45-64" rate="161"/>
                        <category name="&gt; 64" rate="87"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="32"/>
                        <category name="45-64" rate="153"/>
                        <category name="&gt; 64" rate="97"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Placebo QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="11"/>
                        <category name="45-64" rate="84"/>
                        <category name="&gt; 64" rate="47"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="635"/>
                        <category name="Male" rate="640"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 20 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="150"/>
                        <category name="Male" rate="133"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="141"/>
                        <category name="Male" rate="142"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="136"/>
                        <category name="Male" rate="149"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="142"/>
                        <category name="Male" rate="140"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Placebo QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="66"/>
                        <category name="Male" rate="76"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
            </measurements>
            <epochs>
                <epoch name="Randomization">
                    <notes/>
                </epoch>
                <epoch name="Main phase">
                    <duration>P42D</duration>
                    <notes/>
                </epoch>
            </epochs>
            <activities>
                <studyActivity name="Randomization">
                    <activity>
                        <predefined>RANDOMIZATION</predefined>
                    </activity>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 20 mg QD"/>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <usedBy epoch="Randomization" arm="Olmesartan 40 mg QD"/>
                    <usedBy epoch="Randomization" arm="Placebo QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 20">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="20.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 20 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 40">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 80">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="80.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Olmesartan">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Olmesartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Olmesartan 40 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Placebo">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="0.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Placebo"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Placebo QD"/>
                    <notes/>
                </studyActivity>
            </activities>
            <notes>
                <note source="CLINICALTRIALS">NCT00696241</note>
                <note source="MANUAL">This is one of the "main studies" supporting the Edarbi application for monotherapy identified in the EMA EPAR available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002293/WC500119206.pdf

Retrieved from ClinicalTrials.gov using the Takeda internal study identifier 491-008.</note>
            </notes>
        </study>
        <study name="TAK491-011 / NCT00591253">
            <indication name="Hypertensive disorder">
                <notes>
                    <note source="CLINICALTRIALS">Hypertension</note>
                </notes>
            </indication>
            <characteristics>
                <title>
                    <value>Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension</value>
                    <notes>
                        <note source="CLINICALTRIALS">Brief title: Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension

Official title: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Black Subjects With Essential Hypertension</note>
                    </notes>
                </title>
                <allocation>
                    <value>RANDOMIZED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </allocation>
                <blinding>
                    <value>DOUBLE_BLIND</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </blinding>
                <centers>
                    <value>64</value>
                    <notes>
                        <note source="CLINICALTRIALS">Alabaster, Alabama, United States
Huntsville, Alabama, United States
Tempe, Arizona, United States
Freemont, California, United States
Garden Grove, California, United States
Long Beach, California, United States
Riverside, California, United States
Sacramento, California, United States
San Diego, California, United States
Whittier, California, United States
Newark, Delaware, United States
Hialeah, Florida, United States
Hollywood, Florida, United States
Miami, Florida, United States
Pembroke Pines, Florida, United States
Atlanta, Georgia, United States
Waycross, Georgia, United States
Chicago, Illinois, United States
Avon, Indiana, United States
Elkhart, Indiana, United States
Indianapolis, Indiana, United States
Lexington, Kentucky, United States
Baltimore, Maryland, United States
Ann Arbor, Michigan, United States
Bingham Farms, Michigan, United States
Southfield, Michigan, United States
Florissant, Missouri, United States
Brooklyn, New York, United States
Hickory, North Carolina, United States
Raleigh, North Carolina, United States
Salisbury, North Carolina, United States
Shelby, North Carolina, United States
Akron, Ohio, United States
Centerville, Ohio, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Willoughby Hills, Ohio, United States
Zanesville, Ohio, United States
Oklahoma City, Oklahoma, United States
Downingtown, Pennsylvania, United States
Jenkintown, Pennsylvania, United States
Anderson, South Carolina, United States
Charleston, South Carolina, United States
Simpsonville, South Carolina, United States
Spartanburg, South Carolina, United States
Dallas, Texas, United States
Friendswood, Texas, United States
Houston, Texas, United States
Irving, Texas, United States
Katy, Texas, United States
Missouri City, Texas, United States
North Richland Hills, Texas, United States
Pearland, Texas, United States
Sugarland, Texas, United States
Riverton, Utah, United States
Salt Lake City, Utah, United States
Arlington, Virginia, United States
Burke, Virginia, United States
Manassas, Virginia, United States
Port Orchard, Washington, United States
Aguas Buenas, Puerto Rico
Aibonito, Puerto Rico
Loiza, Puerto Rico
San Juan, Puerto Rico
</note>
                    </notes>
                </centers>
                <objective>
                    <value>The purpose of this study is to evaluate the effectiveness and safety of azilsartanmedoxomil compared to placebo, once daily (QD), in African-American participants withessential hypertension.</value>
                    <notes>
                        <note source="CLINICALTRIALS">The purpose of this study is to evaluate the effectiveness and safety of azilsartanmedoxomil compared to placebo, once daily (QD), in African-American participants withessential hypertension.</note>
                    </notes>
                </objective>
                <study_start>
                    <value>2007-10-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">October 2007</note>
                    </notes>
                </study_start>
                <study_end>
                    <value>2009-04-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">April 2009</note>
                    </notes>
                </study_end>
                <status>
                    <value>COMPLETED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Completed</note>
                    </notes>
                </status>
                <inclusion>
                    <value>1. The participant has essential hypertension (defined as sitting trough clinic systolicblood pressure between 150 and 180 mm Hg, inclusive at Day -1) and 24-hour meansystolic blood pressure 130-170 mm Hg, inclusive, at Day 1.

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Clinical laboratory evaluations within the reference range for the testing laboratoryunless the results are deemed not clinically significant for inclusion into thisstudy by the investigator.

4. Willing to discontinue current antihypertensive medication.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria:

1. The participant has essential hypertension (defined as sitting trough clinic systolicblood pressure between 150 and 180 mm Hg, inclusive at Day -1) and 24-hour meansystolic blood pressure 130-170 mm Hg, inclusive, at Day 1.

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Clinical laboratory evaluations within the reference range for the testing laboratoryunless the results are deemed not clinically significant for inclusion into thisstudy by the investigator.

4. Willing to discontinue current antihypertensive medication.

Exclusion Criteria:

1. Has sitting trough clinic diastolic blood pressure greater than 114 mm Hg.

2. Baseline 24 hour ambulatory blood pressure monitor reading of insufficient quality.

3. Hypersensitive to angiotensin II receptor blockers.

4. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

5. Clinically significant cardiac conduction defects.

6. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

7. Secondary hypertension of any etiology.

8. Non-compliant with study medication during run-in period.

9. Severe renal dysfunction or disease (based on calculated creatinine clearance lessthan 30 mL/min/1.73 m2) at Screening.

10. Known or suspected unilateral or bilateral renal artery stenosis.

11. History of drug abuse or a history of alcohol abuse within the past 2 years.

12. Previous history of cancer that has not been in remission for at least 5 years priorto the first dose of study drug.

13. Type 1 or poorly controlled type 2 diabetes mellitus.

14. Alanine aminotransferase level of greater than 2.5 times the upper limit of normal,active liver disease, or jaundice.

15. Hyperkalemia.

16. Upper arm circumference less than 24 cm or greater than 42 cm.

17. Works night (3rd) shift.

18. Currently is participating in another investigational study or has participated in aninvestigational study within 30 days prior to randomization.

19. Any other serious disease or condition at Screening (or Randomization) that wouldcompromise participant safety, might affect life expectancy, or make it difficult tosuccessfully manage and follow the participant according to the protocol.

20. Randomized in a previous azilsartan medoxomil study.

21. Is required to take or continues taking any disallowed medication, prescriptionmedication, herbal treatment or over-the counter medication that may interfere withevaluation of the study medication.</note>
                    </notes>
                </inclusion>
                <exclusion>
                    <value>1. Has sitting trough clinic diastolic blood pressure greater than 114 mm Hg.

2. Baseline 24 hour ambulatory blood pressure monitor reading of insufficient quality.

3. Hypersensitive to angiotensin II receptor blockers.

4. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

5. Clinically significant cardiac conduction defects.

6. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

7. Secondary hypertension of any etiology.

8. Non-compliant with study medication during run-in period.

9. Severe renal dysfunction or disease (based on calculated creatinine clearance lessthan 30 mL/min/1.73 m2) at Screening.

10. Known or suspected unilateral or bilateral renal artery stenosis.

11. History of drug abuse or a history of alcohol abuse within the past 2 years.

12. Previous history of cancer that has not been in remission for at least 5 years priorto the first dose of study drug.

13. Type 1 or poorly controlled type 2 diabetes mellitus.

14. Alanine aminotransferase level of greater than 2.5 times the upper limit of normal,active liver disease, or jaundice.

15. Hyperkalemia.

16. Upper arm circumference less than 24 cm or greater than 42 cm.

17. Works night (3rd) shift.

18. Currently is participating in another investigational study or has participated in aninvestigational study within 30 days prior to randomization.

19. Any other serious disease or condition at Screening (or Randomization) that wouldcompromise participant safety, might affect life expectancy, or make it difficult tosuccessfully manage and follow the participant according to the protocol.

20. Randomized in a previous azilsartan medoxomil study.

21. Is required to take or continues taking any disallowed medication, prescriptionmedication, herbal treatment or over-the counter medication that may interfere withevaluation of the study medication.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria:

1. The participant has essential hypertension (defined as sitting trough clinic systolicblood pressure between 150 and 180 mm Hg, inclusive at Day -1) and 24-hour meansystolic blood pressure 130-170 mm Hg, inclusive, at Day 1.

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Clinical laboratory evaluations within the reference range for the testing laboratoryunless the results are deemed not clinically significant for inclusion into thisstudy by the investigator.

4. Willing to discontinue current antihypertensive medication.

Exclusion Criteria:

1. Has sitting trough clinic diastolic blood pressure greater than 114 mm Hg.

2. Baseline 24 hour ambulatory blood pressure monitor reading of insufficient quality.

3. Hypersensitive to angiotensin II receptor blockers.

4. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

5. Clinically significant cardiac conduction defects.

6. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

7. Secondary hypertension of any etiology.

8. Non-compliant with study medication during run-in period.

9. Severe renal dysfunction or disease (based on calculated creatinine clearance lessthan 30 mL/min/1.73 m2) at Screening.

10. Known or suspected unilateral or bilateral renal artery stenosis.

11. History of drug abuse or a history of alcohol abuse within the past 2 years.

12. Previous history of cancer that has not been in remission for at least 5 years priorto the first dose of study drug.

13. Type 1 or poorly controlled type 2 diabetes mellitus.

14. Alanine aminotransferase level of greater than 2.5 times the upper limit of normal,active liver disease, or jaundice.

15. Hyperkalemia.

16. Upper arm circumference less than 24 cm or greater than 42 cm.

17. Works night (3rd) shift.

18. Currently is participating in another investigational study or has participated in aninvestigational study within 30 days prior to randomization.

19. Any other serious disease or condition at Screening (or Randomization) that wouldcompromise participant safety, might affect life expectancy, or make it difficult tosuccessfully manage and follow the participant according to the protocol.

20. Randomized in a previous azilsartan medoxomil study.

21. Is required to take or continues taking any disallowed medication, prescriptionmedication, herbal treatment or over-the counter medication that may interfere withevaluation of the study medication.</note>
                    </notes>
                </exclusion>
                <references/>
                <source>
                    <value>CLINICALTRIALS</value>
                    <notes>
                        <note source="CLINICALTRIALS">http://clinicaltrials.gov/show/NCT00591253</note>
                    </notes>
                </source>
                <creation_date>
                    <value>2012-09-24</value>
                    <notes>
                        <note source="CLINICALTRIALS">Information obtained from ClinicalTrials.gov on September 20, 2012</note>
                    </notes>
                </creation_date>
            </characteristics>
            <studyOutcomeMeasures>
                <studyOutcomeMeasure id="endpoint-SBP 24-hour mean" primary="true">
                    <endpoint name="SBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="SBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure
Description: The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 24-hour mean" primary="false">
                    <endpoint name="DBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="DBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
Description: The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP daytime mean" primary="false">
                    <endpoint name="SBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP daytime mean" primary="false">
                    <endpoint name="DBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP nighttime mean" primary="false">
                    <endpoint name="SBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP nighttime mean" primary="false">
                    <endpoint name="DBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP 12-hour mean" primary="false">
                    <endpoint name="SBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 12-hour mean" primary="false">
                    <endpoint name="DBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP trough mean" primary="false">
                    <endpoint name="SBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP trough mean" primary="false">
                    <endpoint name="DBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP response (clinic)" primary="false">
                    <endpoint name="SBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as &lt; 140 mm Hg and/or Reduction From Baseline  20 mm Hg
Description: Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP response (clinic)" primary="false">
                    <endpoint name="DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as &lt; 90 mm Hg and/or Reduction From Baseline  10 mm Hg
Description: Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)" primary="false">
                    <endpoint name="SBP and DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
Description: Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-SAE" primary="false">
                    <adverseEvent name="SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, serious adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Vomiting" primary="false">
                    <adverseEvent name="Vomiting"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Vomiting (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Diabetic ketoacidosis" primary="false">
                    <adverseEvent name="Diabetic ketoacidosis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Diabetic ketoacidosis (Metabolism and nutrition disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cerebral haemorrhage" primary="false">
                    <adverseEvent name="Cerebral haemorrhage"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cerebral haemorrhage (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Asthma" primary="false">
                    <adverseEvent name="Asthma"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Asthma (Respiratory, thoracic and mediastinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Non-SAE" primary="false">
                    <adverseEvent name="Non-SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, other adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Headache" primary="false">
                    <adverseEvent name="Headache"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Headache (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)" primary="false">
                    <populationCharacteristic name="Age (cut-off 45, 65)"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Age
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Gender" primary="false">
                    <populationCharacteristic name="Gender"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gender
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
            </studyOutcomeMeasures>
            <arms>
                <arm name="Azilsartan Medoxomil 40 mg QD" size="138">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 40 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Azilsartan Medoxomil 80 mg QD" size="137">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 80 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.</note>
                    </notes>
                </arm>
                <arm name="Placebo QD" size="138">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Placebo QD
Arm Type: Placebo Comparator

Intervention Name: Placebo
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.</note>
                    </notes>
                </arm>
            </arms>
            <measurements>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-5.15" sampleSize="94" stdDev="7.901718167588617"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-6.99" sampleSize="101" stdDev="7.9193019894432615"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.34" sampleSize="94" stdDev="7.911413527303449"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-4.93" sampleSize="94" stdDev="7.097003311257506"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-7.27" sampleSize="101" stdDev="7.095212188511348"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.49" sampleSize="94" stdDev="7.087307951542673"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-5.08" sampleSize="94" stdDev="7.407254822132152"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-7.24" sampleSize="101" stdDev="7.416808208387216"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.34" sampleSize="94" stdDev="7.407254822132152"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-5.48" sampleSize="134" stdDev="8.73975686160662"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-5.32" sampleSize="130" stdDev="8.733743756259397"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-2.36" sampleSize="133" stdDev="8.730149884165794"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-4.48" sampleSize="94" stdDev="9.210591729091025"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-7.23" sampleSize="101" stdDev="9.205686068946736"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.44" sampleSize="94" stdDev="9.210591729091025"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="71" sampleSize="134"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="72" sampleSize="130"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="53" sampleSize="133"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-4.77" sampleSize="94" stdDev="10.916975038901573"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.28" sampleSize="101" stdDev="10.904115048916164"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.73" sampleSize="94" stdDev="10.907279679186741"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.7" sampleSize="94" stdDev="11.19814047063172"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-10.11" sampleSize="101" stdDev="11.195561441928673"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-2.4" sampleSize="94" stdDev="11.207835830346554"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.7" sampleSize="94" stdDev="10.306167376867116"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-10.48" sampleSize="101" stdDev="10.311172387270034"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-2.7" sampleSize="94" stdDev="10.325558096296781"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="43" sampleSize="134"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="45" sampleSize="130"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="22" sampleSize="133"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.53" sampleSize="94" stdDev="10.60672352802693"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-10.4" sampleSize="101" stdDev="10.61266865590366"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-2.43" sampleSize="94" stdDev="10.626114247456595"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-9.51" sampleSize="134" stdDev="15.395863080711"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-9.58" sampleSize="130" stdDev="15.403769993089353"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-3.04" sampleSize="133" stdDev="15.37290593869617"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.97" sampleSize="94" stdDev="12.633053708426953"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-10.34" sampleSize="101" stdDev="12.652793406991199"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-3.06" sampleSize="94" stdDev="12.671835147286284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="56" sampleSize="134"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="49" sampleSize="130"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="33" sampleSize="133"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.14" sampleSize="94" stdDev="13.398987125898733"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-10.99" sampleSize="101" stdDev="13.406534078575268"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-2.28" sampleSize="94" stdDev="13.428073205043232"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Asthma"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Asthma"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Asthma"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="138"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cerebral haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cerebral haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cerebral haemorrhage"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="138"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diabetic ketoacidosis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diabetic ketoacidosis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diabetic ketoacidosis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="138"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="6" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="9" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="3" sampleSize="138"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="6" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="9" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="3" sampleSize="138"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="3" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="138"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="137"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="138"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="102"/>
                        <category name="45-64" rate="265"/>
                        <category name="&gt; 64" rate="46"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="29"/>
                        <category name="45-64" rate="94"/>
                        <category name="&gt; 64" rate="15"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="37"/>
                        <category name="45-64" rate="86"/>
                        <category name="&gt; 64" rate="14"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Placebo QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="36"/>
                        <category name="45-64" rate="85"/>
                        <category name="&gt; 64" rate="17"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="236"/>
                        <category name="Male" rate="177"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="78"/>
                        <category name="Male" rate="60"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="80"/>
                        <category name="Male" rate="57"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Placebo QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="78"/>
                        <category name="Male" rate="60"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
            </measurements>
            <epochs>
                <epoch name="Randomization">
                    <notes/>
                </epoch>
                <epoch name="Main phase">
                    <duration>P42D</duration>
                    <notes/>
                </epoch>
            </epochs>
            <activities>
                <studyActivity name="Randomization">
                    <activity>
                        <predefined>RANDOMIZATION</predefined>
                    </activity>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <usedBy epoch="Randomization" arm="Placebo QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 40">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan medoxomil 1">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="80.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Placebo">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="0.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Placebo"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Placebo QD"/>
                    <notes/>
                </studyActivity>
            </activities>
            <notes>
                <note source="CLINICALTRIALS">NCT00591253</note>
                <note source="MANUAL">This is one of the "main studies" supporting the Edarbi application for monotherapy identified in the EMA EPAR available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002293/WC500119206.pdf

Retrieved from ClinicalTrials.gov using the Takeda internal study identifier 491-011.</note>
            </notes>
        </study>
        <study name="TAK491-019 / NCT00696436">
            <indication name="Hypertensive disorder">
                <notes>
                    <note source="CLINICALTRIALS">Hypertension</note>
                </notes>
            </indication>
            <characteristics>
                <title>
                    <value>An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Brief title: An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Official title: A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension</note>
                    </notes>
                </title>
                <allocation>
                    <value>RANDOMIZED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </allocation>
                <blinding>
                    <value>DOUBLE_BLIND</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </blinding>
                <centers>
                    <value>131</value>
                    <notes>
                        <note source="CLINICALTRIALS">Alabaster, Alabama, United States
Ozark, Alabama, United States
Green Valley, Arizona, United States
Litchfield Park, Arizona, United States
Mesa, Arizona, United States
Tempe, Arizona, United States
Carmichael, California, United States
Chula Vista, California, United States
Lincoln, California, United States
Mission Viejo, California, United States
National City, California, United States
Pasadena, California, United States
Riverside, California, United States
Sacramento, California, United States
San Diego, California, United States
San Dimas, California, United States
San Fransisco, California, United States
San Ramon, California, United States
Santa Ana, California, United States
Vista, California, United States
Colorado Springs, Colorado, United States
Denver, Colorado, United States
Littleton, Colorado, United States
Longmont, Colorado, United States
Cape Coral, Florida, United States
Clearwater, Florida, United States
Largo, Florida, United States
Miami, Florida, United States
New Port Richey, Florida, United States
New Smyrna Beach, Florida, United States
Palm Harbor, Florida, United States
Tallahassee, Florida, United States
Dunwoody, Georgia, United States
Roswell, Georgia, United States
Arlington Heights, Illinois, United States
Belleville, Illinois, United States
Champaign, Illinois, United States
Chicago, Illinois, United States
Peoria, Illinois, United States
Vernon Hills, Illinois, United States
Evansville, Indiana, United States
Indianapolis, Indiana, United States
Terre Haute, Indiana, United States
Kansas City, Kansas, United States
Overland Park, Kansas, United States
Shawnee, Kansas, United States
Biddeford, Maine, United States
Norwood, Maine, United States
Baltimore, Maryland, United States
Towson, Maryland, United States
Brooklyn Center, Minnesota, United States
Chesterfield, Missouri, United States
Jefferson City, Missouri, United States
Kansas City, Missouri, United States
St Louis, Missouri, United States
Billings, Montana, United States
Las Vegas, Nevada, United States
Margate, New Jersey, United States
Glens Falls, New York, United States
Great Neck, New York, United States
New Hyde Park, New York, United States
New Windsor, New York, United States
New York, New York, United States
Charlotte, North Carolina, United States
Raleigh, North Carolina, United States
Columbus, Ohio, United States
Norman, Oklahoma, United States
Tulsa, Oklahoma, United States
Yukon, Oklahoma, United States
Ashland, Oregon, United States
Eugene, Oregon, United States
Medford, Oregon, United States
Portland, Oregon, United States
Pittsburgh, Pennsylvania, United States
Tipton, Pennsylvania, United States
Charleston, South Carolina, United States
Murrells Inlet, South Carolina, United States
North Charleston, South Carolina, United States
Cleveland, Tennessee, United States
Bedford, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Missouri City, Texas, United States
San Antonio, Texas, United States
Sugarland, Texas, United States
Tacoma, Washington, United States
Carlos Paz, Crdoba, Argentina
Guaymayen, Mendoza, Argentina
Baha Blanca, Argentina
Berazategui, Argentina
Buenos Aires, Argentina
Corrientes, Argentina
Crdoba, Argentina
Haedo Pcia. de Buenos Aires, Argentina
Jujuy, Argentina
La Plata, Argentina
Ramos Meja Pcia. de Buenos Aires, Argentina
Rosario, Argentina
Salta, Argentina
San Miguel de Tucumn, Argentina
Belo Horizonte, Brazil
Campinas, Brazil
Fortaleza, Brazil
Goiaenia, Brazil
Joildille, Brazil
Porto Alegre, Brazil
Rio Janeiro, Brazil
Sao Paulo, Brazil
Sorocava, Brazil
Tijuana, Baja California, Mexico
Len, Guanajuato, Mexico
Guadalajara, Jalapa, Mexico
Monterrey, Nuevo Leon, Mexico
Xalapa, Veracruz, Mexico
Aguascalientes, Mexico
Chihuahua, Mexico
Mexico City, Mexico
Quertaro, Mexico
San Luis Potos, Mexico
Arequipa, Peru
Cusco, Peru
Huaura, Peru
Ica, Peru
Lima, Peru
Trujillo, Peru
Aguas Buenas, Puerto Rico
Carolina, Puerto Rico
Jardines de Loiza, Puerto Rico
Orocovis, Puerto Rico
Ponce, Puerto Rico
San Juan, Puerto Rico
</note>
                    </notes>
                </centers>
                <objective>
                    <value>The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil,once daily (QD), compared to placebo, valsartan and olmesartan in participants withessential hypertension.</value>
                    <notes>
                        <note source="CLINICALTRIALS">The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil,once daily (QD), compared to placebo, valsartan and olmesartan in participants withessential hypertension.</note>
                    </notes>
                </objective>
                <study_start>
                    <value>2008-04-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">April 2008</note>
                    </notes>
                </study_start>
                <study_end>
                    <value>2009-08-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">August 2009</note>
                    </notes>
                </study_end>
                <status>
                    <value>COMPLETED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Completed</note>
                    </notes>
                </status>
                <inclusion>
                    <value>1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg,inclusive, at Day -1 and 24-hour mean systolic blood pressure between 130 and 170 mmHg, inclusive, at Day 1).

2. Capable of understanding and complying with protocol requirements.

3. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study

4. Clinical laboratory evaluations within the reference range for the testing laboratoryor the results are deemed not clinically significant for inclusion into this study bythe investigator.

5. Willing to discontinue current antihypertensive medications at Screening Day 21visit. If the participant is on amlodipine prior to Screening, the participant iswilling to discontinue this medication at Screening Day -28.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria:

1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg,inclusive, at Day -1 and 24-hour mean systolic blood pressure between 130 and 170 mmHg, inclusive, at Day 1).

2. Capable of understanding and complying with protocol requirements.

3. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study

4. Clinical laboratory evaluations within the reference range for the testing laboratoryor the results are deemed not clinically significant for inclusion into this study bythe investigator.

5. Willing to discontinue current antihypertensive medications at Screening Day 21visit. If the participant is on amlodipine prior to Screening, the participant iswilling to discontinue this medication at Screening Day -28.

Exclusion Criteria:

1. Sitting diastolic blood pressure greater than 114 mm Hg at Day -1 (day prior toRandomization).

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. Taking or expected to take an excluded medication as described in the ExcludedMedications.

4. Hypersensitive to angiotensin II receptor blockers.

5. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

6. Clinically significant cardiac conduction defects.

7. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

8. Secondary hypertension of any etiology.

9. Noncompliant (less than 70% or greater than 130%) with study medication during run-inperiod.

10. Moderate to severe renal dysfunction or disease.

11. Known or suspected unilateral or bilateral renal artery stenosis.

12. History of drug or alcohol abuse within the past 2 years.

13. Previous history of cancer that has not been in remission for at least 5 years priorto the first dose of study drug. (This criterion does not apply to those participantswith basal cell or stage I squamous cell carcinoma of the skin).

14. Type 1 or poorly-controlled type 2 diabetes mellitus (glycosylate hemoglobin greaterthan 8.0%) at Screening.

15. Hyperkalemia as defined by the central laboratory normal reference range atScreening.

16. Alanine aminotransferase level of greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

17. Upper arm circumference less than 24 cm or greater than 42 cm.

18. Works night (3rd) shift (defined as 11 PM [2300] to 7 AM [0700]).

19. Unwilling or unable to comply with the protocol or scheduled appointments.

20. Currently is participating in another investigational study or has participated in aninvestigational study within 30 days prior to Randomization.

21. Any other serious disease or condition at Screening or Randomization that wouldcompromise participant's safety, might affect life expectancy, or make it difficultto successfully manage and follow the subject according to the protocol.

22. Has been randomized in a previous azilsartan medoxomil study.

23. Is required to take or continues taking any disallowed medication, prescriptionmedication, herbal treatment or over-the counter medication that may interfere withevaluation of the study medication.</note>
                    </notes>
                </inclusion>
                <exclusion>
                    <value>1. Sitting diastolic blood pressure greater than 114 mm Hg at Day -1 (day prior toRandomization).

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. Taking or expected to take an excluded medication as described in the ExcludedMedications.

4. Hypersensitive to angiotensin II receptor blockers.

5. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

6. Clinically significant cardiac conduction defects.

7. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

8. Secondary hypertension of any etiology.

9. Noncompliant (less than 70% or greater than 130%) with study medication during run-inperiod.

10. Moderate to severe renal dysfunction or disease.

11. Known or suspected unilateral or bilateral renal artery stenosis.

12. History of drug or alcohol abuse within the past 2 years.

13. Previous history of cancer that has not been in remission for at least 5 years priorto the first dose of study drug. (This criterion does not apply to those participantswith basal cell or stage I squamous cell carcinoma of the skin).

14. Type 1 or poorly-controlled type 2 diabetes mellitus (glycosylate hemoglobin greaterthan 8.0%) at Screening.

15. Hyperkalemia as defined by the central laboratory normal reference range atScreening.

16. Alanine aminotransferase level of greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

17. Upper arm circumference less than 24 cm or greater than 42 cm.

18. Works night (3rd) shift (defined as 11 PM [2300] to 7 AM [0700]).

19. Unwilling or unable to comply with the protocol or scheduled appointments.

20. Currently is participating in another investigational study or has participated in aninvestigational study within 30 days prior to Randomization.

21. Any other serious disease or condition at Screening or Randomization that wouldcompromise participant's safety, might affect life expectancy, or make it difficultto successfully manage and follow the subject according to the protocol.

22. Has been randomized in a previous azilsartan medoxomil study.

23. Is required to take or continues taking any disallowed medication, prescriptionmedication, herbal treatment or over-the counter medication that may interfere withevaluation of the study medication.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria:

1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg,inclusive, at Day -1 and 24-hour mean systolic blood pressure between 130 and 170 mmHg, inclusive, at Day 1).

2. Capable of understanding and complying with protocol requirements.

3. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study

4. Clinical laboratory evaluations within the reference range for the testing laboratoryor the results are deemed not clinically significant for inclusion into this study bythe investigator.

5. Willing to discontinue current antihypertensive medications at Screening Day 21visit. If the participant is on amlodipine prior to Screening, the participant iswilling to discontinue this medication at Screening Day -28.

Exclusion Criteria:

1. Sitting diastolic blood pressure greater than 114 mm Hg at Day -1 (day prior toRandomization).

2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

3. Taking or expected to take an excluded medication as described in the ExcludedMedications.

4. Hypersensitive to angiotensin II receptor blockers.

5. History of myocardial infarction, heart failure, unstable angina, coronary arterybypass graft, percutaneous coronary intervention, hypertensive encephalopathy,cerebrovascular accident, or transient ischemic attack.

6. Clinically significant cardiac conduction defects.

7. Hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

8. Secondary hypertension of any etiology.

9. Noncompliant (less than 70% or greater than 130%) with study medication during run-inperiod.

10. Moderate to severe renal dysfunction or disease.

11. Known or suspected unilateral or bilateral renal artery stenosis.

12. History of drug or alcohol abuse within the past 2 years.

13. Previous history of cancer that has not been in remission for at least 5 years priorto the first dose of study drug. (This criterion does not apply to those participantswith basal cell or stage I squamous cell carcinoma of the skin).

14. Type 1 or poorly-controlled type 2 diabetes mellitus (glycosylate hemoglobin greaterthan 8.0%) at Screening.

15. Hyperkalemia as defined by the central laboratory normal reference range atScreening.

16. Alanine aminotransferase level of greater than 2.5 times the upper limit of normal,active liver disease, or jaundice at Screening.

17. Upper arm circumference less than 24 cm or greater than 42 cm.

18. Works night (3rd) shift (defined as 11 PM [2300] to 7 AM [0700]).

19. Unwilling or unable to comply with the protocol or scheduled appointments.

20. Currently is participating in another investigational study or has participated in aninvestigational study within 30 days prior to Randomization.

21. Any other serious disease or condition at Screening or Randomization that wouldcompromise participant's safety, might affect life expectancy, or make it difficultto successfully manage and follow the subject according to the protocol.

22. Has been randomized in a previous azilsartan medoxomil study.

23. Is required to take or continues taking any disallowed medication, prescriptionmedication, herbal treatment or over-the counter medication that may interfere withevaluation of the study medication.</note>
                    </notes>
                </exclusion>
                <references>
                    <pubMedId>21282560</pubMedId>
                </references>
                <source>
                    <value>CLINICALTRIALS</value>
                    <notes>
                        <note source="CLINICALTRIALS">http://clinicaltrials.gov/show/NCT00696436</note>
                    </notes>
                </source>
                <creation_date>
                    <value>2012-09-24</value>
                    <notes>
                        <note source="CLINICALTRIALS">Information obtained from ClinicalTrials.gov on September 20, 2012</note>
                    </notes>
                </creation_date>
            </characteristics>
            <studyOutcomeMeasures>
                <studyOutcomeMeasure id="endpoint-SBP 24-hour mean" primary="true">
                    <endpoint name="SBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="SBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
Description: The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 24-hour mean" primary="false">
                    <endpoint name="DBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="DBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
Description: The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP daytime mean" primary="false">
                    <endpoint name="SBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP daytime mean" primary="false">
                    <endpoint name="DBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP nighttime mean" primary="false">
                    <endpoint name="SBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP nighttime mean" primary="false">
                    <endpoint name="DBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP 12-hour mean" primary="false">
                    <endpoint name="SBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 12-hour mean" primary="false">
                    <endpoint name="DBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP trough mean" primary="false">
                    <endpoint name="SBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP trough mean" primary="false">
                    <endpoint name="DBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP response (clinic)" primary="false">
                    <endpoint name="SBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as &lt; 140 mm Hg and/or Reduction From Baseline  20 mm Hg
Description: Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP response (clinic)" primary="false">
                    <endpoint name="DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as &lt; 90 mm Hg and/or Reduction From Baseline  10 mm Hg
Description: Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)" primary="false">
                    <endpoint name="SBP and DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
Description: Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.
Time frame: Baseline and Week 6.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-SAE" primary="false">
                    <adverseEvent name="SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, serious adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Eye irritation" primary="false">
                    <adverseEvent name="Eye irritation"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Eye irritation (Eye disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Abdominal adhesions" primary="false">
                    <adverseEvent name="Abdominal adhesions"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Abdominal adhesions (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage" primary="false">
                    <adverseEvent name="Gastrointestinal haemorrhage"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gastrointestinal haemorrhage (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cholecystitis" primary="false">
                    <adverseEvent name="Cholecystitis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cholecystitis (Hepatobiliary disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cholelithiasis" primary="false">
                    <adverseEvent name="Cholelithiasis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cholelithiasis (Hepatobiliary disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cellulitis" primary="false">
                    <adverseEvent name="Cellulitis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cellulitis (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Diverticulitis" primary="false">
                    <adverseEvent name="Diverticulitis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Diverticulitis (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Infected bites" primary="false">
                    <adverseEvent name="Infected bites"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Infected bites (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Fall" primary="false">
                    <adverseEvent name="Fall"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Fall (Injury, poisoning and procedural complications)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Intentional overdose" primary="false">
                    <adverseEvent name="Intentional overdose"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Intentional overdose (Injury, poisoning and procedural complications)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Subdural haematoma" primary="false">
                    <adverseEvent name="Subdural haematoma"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Subdural haematoma (Injury, poisoning and procedural complications)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Blood pressure increased" primary="false">
                    <adverseEvent name="Blood pressure increased"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Blood pressure increased (Investigations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Breast cancer" primary="false">
                    <adverseEvent name="Breast cancer"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Breast cancer (Neoplasms benign, malignant and unspecified (incl cysts and polyps))</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Partial seizures" primary="false">
                    <adverseEvent name="Partial seizures"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Partial seizures (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Dysfunctional uterine bleeding" primary="false">
                    <adverseEvent name="Dysfunctional uterine bleeding"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Dysfunctional uterine bleeding (Reproductive system and breast disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis" primary="false">
                    <adverseEvent name="Deep vein thrombosis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Deep vein thrombosis (Vascular disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Non-SAE" primary="false">
                    <adverseEvent name="Non-SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, other adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Headache" primary="false">
                    <adverseEvent name="Headache"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Headache (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)" primary="false">
                    <populationCharacteristic name="Age (cut-off 45, 65)"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Age
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Gender" primary="false">
                    <populationCharacteristic name="Gender"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gender
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
            </studyOutcomeMeasures>
            <arms>
                <arm name="Azilsartan Medoxomil 40 mg QD" size="280">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 40 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</note>
                    </notes>
                </arm>
                <arm name="Azilsartan Medoxomil 80 mg QD" size="285">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 80 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</note>
                    </notes>
                </arm>
                <arm name="Valsartan 320 mg QD" size="282">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Valsartan 320 mg QD
Arm Type: Active Comparator

Intervention Name: Valsartan
Intervention Type: Drug
Intervention Description: Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</note>
                    </notes>
                </arm>
                <arm name="Olmesartan 40 mg QD" size="290">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Olmesartan 40 mg QD
Arm Type: Active Comparator

Intervention Name: Olmesartan
Intervention Type: Drug
Intervention Description: Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</note>
                    </notes>
                </arm>
                <arm name="Placebo QD" size="154">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Placebo QD
Arm Type: Placebo Comparator

Intervention Name: Placebo
Intervention Type: Drug
Intervention Description: Matching placebo, orally, once daily for up to six weeks.</note>
                    </notes>
                </arm>
            </arms>
            <measurements>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-9.16" sampleSize="237" stdDev="8.343983940540634"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-10.13" sampleSize="229" stdDev="8.338143018682278"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.82" sampleSize="254" stdDev="8.351185784066836"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="0.01" sampleSize="134" stdDev="8.346178406911752"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-7.42" sampleSize="234" stdDev="8.36749102180576"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.65" sampleSize="237" stdDev="7.2663476382567875"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-9.43" sampleSize="229" stdDev="7.263718056202347"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.74" sampleSize="254" stdDev="7.267444117432208"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.07" sampleSize="134" stdDev="7.258049738049471"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-7.09" sampleSize="234" stdDev="7.2813998654104966"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.96" sampleSize="237" stdDev="7.851350202353733"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-9.8" sampleSize="229" stdDev="7.838762402318366"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.82" sampleSize="254" stdDev="7.84118970565054"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="0.01" sampleSize="134" stdDev="7.836841583188983"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-7.23" sampleSize="234" stdDev="7.862688089960074"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-6.97" sampleSize="269" stdDev="9.053473145704913"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.27" sampleSize="270" stdDev="9.053853875560396"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-6.1" sampleSize="283" stdDev="9.05056086659827"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.76" sampleSize="148" stdDev="9.05115064508375"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-5.11" sampleSize="271" stdDev="9.054142698234882"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.65" sampleSize="237" stdDev="8.313194331903953"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.54" sampleSize="229" stdDev="8.323010272731857"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-7.82" sampleSize="254" stdDev="8.319311029165817"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="0.1" sampleSize="134" stdDev="8.311450896203382"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-6.26" sampleSize="234" stdDev="8.321599846183426"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="185" sampleSize="269"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="192" sampleSize="270"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="193" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="65" sampleSize="148"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="173" sampleSize="271"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.69" sampleSize="236" stdDev="9.954764889237715"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.61" sampleSize="229" stdDev="9.942214089426963"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-8.25" sampleSize="254" stdDev="9.944923529117759"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.69" sampleSize="134" stdDev="9.943643899496804"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-6.22" sampleSize="234" stdDev="9.95838511004671"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-14.03" sampleSize="237" stdDev="11.76163049921226"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-15.55" sampleSize="229" stdDev="11.75814360347755"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-12.23" sampleSize="254" stdDev="11.76178455847581"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.1" sampleSize="134" stdDev="11.761050293234868"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-10.44" sampleSize="234" stdDev="11.778735076399334"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-13.42" sampleSize="237" stdDev="10.62241497965505"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-14.53" sampleSize="229" stdDev="10.623187657195931"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-11.99" sampleSize="254" stdDev="10.614293382039147"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.25" sampleSize="134" stdDev="10.615042439858637"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-10.22" sampleSize="234" stdDev="10.646752744381734"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="132" sampleSize="269"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="142" sampleSize="270"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="126" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="27" sampleSize="148"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="119" sampleSize="271"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-13.73" sampleSize="237" stdDev="11.145838326478632"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-15.02" sampleSize="229" stdDev="11.137701019510265"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-12.16" sampleSize="254" stdDev="11.14022683790595"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.11" sampleSize="134" stdDev="11.147530937386987"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-10.26" sampleSize="234" stdDev="11.166852734768199"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-16.38" sampleSize="269" stdDev="15.728769468715601"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-16.74" sampleSize="270" stdDev="15.725114625973317"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-13.2" sampleSize="283" stdDev="15.729134591578775"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-1.83" sampleSize="148" stdDev="15.730023903351194"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-11.31" sampleSize="271" stdDev="15.721284139662384"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.28" sampleSize="237" stdDev="11.977157759669028"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-13.32" sampleSize="229" stdDev="11.985134792733874"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-11.9" sampleSize="254" stdDev="11.98490784278294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.31" sampleSize="134" stdDev="11.980991194387883"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-9.66" sampleSize="234" stdDev="11.992893895970232"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="152" sampleSize="269"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="156" sampleSize="270"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="138" sampleSize="283"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="33" sampleSize="148"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="132" sampleSize="271"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.46" sampleSize="236" stdDev="13.211570686334005"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-13.38" sampleSize="229" stdDev="13.210887214718019"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <continuousMeasurement mean="-11.65" sampleSize="254" stdDev="13.212085906472149"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Placebo QD"/>
                    <continuousMeasurement mean="-0.55" sampleSize="134" stdDev="13.219605742986436"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <continuousMeasurement mean="-9.14" sampleSize="234" stdDev="13.231955637773277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Abdominal adhesions"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Abdominal adhesions"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Abdominal adhesions"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Abdominal adhesions"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="1" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Abdominal adhesions"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood pressure increased"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood pressure increased"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood pressure increased"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood pressure increased"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood pressure increased"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Breast cancer"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Breast cancer"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Breast cancer"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Breast cancer"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Breast cancer"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholecystitis"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholelithiasis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholelithiasis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholelithiasis"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholelithiasis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cholelithiasis"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diverticulitis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diverticulitis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diverticulitis"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diverticulitis"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diverticulitis"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dysfunctional uterine bleeding"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dysfunctional uterine bleeding"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dysfunctional uterine bleeding"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dysfunctional uterine bleeding"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dysfunctional uterine bleeding"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Eye irritation"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Eye irritation"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Eye irritation"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Eye irritation"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Eye irritation"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Fall"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Fall"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Fall"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Fall"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="1" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Fall"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastrointestinal haemorrhage"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="18" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="12" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="23" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="14" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="21" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Infected bites"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Infected bites"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Infected bites"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Infected bites"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Infected bites"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Intentional overdose"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Intentional overdose"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Intentional overdose"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Intentional overdose"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Intentional overdose"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="18" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="12" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="23" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="14" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="21" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Partial seizures"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Partial seizures"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Partial seizures"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Partial seizures"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Partial seizures"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="2" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="3" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="4" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="2" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="3" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Subdural haematoma"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="280"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Subdural haematoma"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="284"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Subdural haematoma"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="290"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Subdural haematoma"/>
                    <arm name="Placebo QD"/>
                    <rateMeasurement rate="0" sampleSize="155"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Subdural haematoma"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="277"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="194"/>
                        <category name="45-64" rate="815"/>
                        <category name="&gt; 64" rate="282"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="41"/>
                        <category name="45-64" rate="170"/>
                        <category name="&gt; 64" rate="69"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="38"/>
                        <category name="45-64" rate="184"/>
                        <category name="&gt; 64" rate="63"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="39"/>
                        <category name="45-64" rate="185"/>
                        <category name="&gt; 64" rate="66"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Placebo QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="20"/>
                        <category name="45-64" rate="98"/>
                        <category name="&gt; 64" rate="36"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="56"/>
                        <category name="45-64" rate="178"/>
                        <category name="&gt; 64" rate="48"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="592"/>
                        <category name="Male" rate="699"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="133"/>
                        <category name="Male" rate="147"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="134"/>
                        <category name="Male" rate="151"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Olmesartan 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="131"/>
                        <category name="Male" rate="159"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Placebo QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="64"/>
                        <category name="Male" rate="90"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Valsartan 320 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="130"/>
                        <category name="Male" rate="152"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
            </measurements>
            <epochs>
                <epoch name="Randomization">
                    <notes/>
                </epoch>
                <epoch name="Main phase">
                    <duration>P42D</duration>
                    <notes/>
                </epoch>
            </epochs>
            <activities>
                <studyActivity name="Randomization">
                    <activity>
                        <predefined>RANDOMIZATION</predefined>
                    </activity>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <usedBy epoch="Randomization" arm="Olmesartan 40 mg QD"/>
                    <usedBy epoch="Randomization" arm="Placebo QD"/>
                    <usedBy epoch="Randomization" arm="Valsartan 320 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 20-40">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="20.0" maxDose="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 40-80">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="40.0" maxDose="80.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Valsartan">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="160.0" maxDose="320.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Valsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Valsartan 320 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Olmesartan">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="20.0" maxDose="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Olmesartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Olmesartan 40 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Placebo">
                    <activity>
                        <treatment>
                            <drugTreatment>
<fixedDose quantity="0.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</fixedDose>
<drug name="Placebo"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Placebo QD"/>
                    <notes/>
                </studyActivity>
            </activities>
            <notes>
                <note source="CLINICALTRIALS">NCT00696436</note>
                <note source="MANUAL">This is one of the "main studies" supporting the Edarbi application for monotherapy identified in the EMA EPAR available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002293/WC500119206.pdf

Retrieved from ClinicalTrials.gov using the Takeda internal study identifier 491-019.</note>
            </notes>
        </study>
        <study name="TAK491-020 / NCT00760214">
            <indication name="Hypertensive disorder">
                <notes>
                    <note source="CLINICALTRIALS">Hypertension</note>
                </notes>
            </indication>
            <characteristics>
                <title>
                    <value>Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension</value>
                    <notes>
                        <note source="CLINICALTRIALS">Brief title: Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

Official title: A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential Hypertension</note>
                    </notes>
                </title>
                <allocation>
                    <value>RANDOMIZED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </allocation>
                <blinding>
                    <value>DOUBLE_BLIND</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </blinding>
                <centers>
                    <value>72</value>
                    <notes>
                        <note source="CLINICALTRIALS">Pleven, Bulgaria
Plovdiv, Bulgaria
Rouse, Bulgaria
Sofia, Bulgaria
Varna, Bulgaria
Paide, Estonia
Tallinn, Estonia
Tartu, Estonia
Viljandi, Estonia
Joensuu, Finland
Mikkeli, Finland
Tampere, Finland
Turku, Finland
Augsburg, Germany
Bad Krozingen, Germany
Bad Segeberg, Germany
Berlin, Germany
Dortmund, Germany
Dresden, Germany
Essen, Germany
Frankfurt, Germany
Goch, Germany
Grossheirath, Germany
Hamburg, Germany
Karlsruhe, Germany
Koeln, Germany
Kuenzing, Germany
Leipzig, Germany
Luebeck, Germany
Mannheim, Germany
Muenchen, Germany
Nuernberg, Germany
Siegen, Germany
Deurne, Netherlands
Ewijk, Netherlands
Geleen, Netherlands
Lichtenvoorde, Netherlands
Oude Pekela, Netherlands
Rijswijk, Netherlands
Roelofarendsveen, Netherlands
Rotterdam, Netherlands
Wildervank, Netherlands
Gdansk, Poland
Gniewkowo, Poland
Kamieniec Zabkowicki, Poland
Katowice, Poland
Libiaz, Poland
Lodz, Poland
Olawa, Poland
Plock, Poland
Poznan, Poland
Skierniewice, Poland
Tarnow, Poland
Moscow, Russian Federation
Perm, Russian Federation
St Petersburg, Russian Federation
Belgrade, Serbia
Nis, Serbia
Niska Banja, Serbia
Zemun, Serbia
Bratislava, Slovakia
Galanta, Slovakia
Levice, Slovakia
Lucenec, Slovakia
Rimavska Sobota, Slovakia
Boden, Sweden
Gteborg, Sweden
Lule, Sweden
Lund, Sweden
Malm, Sweden
Skene, Sweden
rebro, Sweden
</note>
                    </notes>
                </centers>
                <objective>
                    <value>The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil,once daily (QD), compared to ramipril for treating Essential Hypertension.</value>
                    <notes>
                        <note source="CLINICALTRIALS">The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil,once daily (QD), compared to ramipril for treating Essential Hypertension.</note>
                    </notes>
                </objective>
                <study_start>
                    <value>2008-01-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">January 2008</note>
                    </notes>
                </study_start>
                <study_end>
                    <value>2009-04-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">April 2009</note>
                    </notes>
                </study_end>
                <status>
                    <value>COMPLETED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Completed</note>
                    </notes>
                </status>
                <inclusion>
                    <value>1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg,inclusive).

2. A female participant of childbearing potential who is sexually active agrees to useadequate contraception from screening throughout the duration of the study, andcannot be pregnant.

3. Has clinical laboratory evaluations (including clinical chemistry, hematology, andcomplete urinalysis) within the reference range for the testing laboratory atScreening or the results are deemed not clinically significant for inclusion intothis study by the investigator.

4. Is willing to discontinue current antihypertensive medications at Screening Day -21.If the participant is on amlodipine prior to screening, the participant is willing todiscontinue this medication at Screening Day -28.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria:

1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg,inclusive).

2. A female participant of childbearing potential who is sexually active agrees to useadequate contraception from screening throughout the duration of the study, andcannot be pregnant.

3. Has clinical laboratory evaluations (including clinical chemistry, hematology, andcomplete urinalysis) within the reference range for the testing laboratory atScreening or the results are deemed not clinically significant for inclusion intothis study by the investigator.

4. Is willing to discontinue current antihypertensive medications at Screening Day -21.If the participant is on amlodipine prior to screening, the participant is willing todiscontinue this medication at Screening Day -28.

Exclusion Criteria:

1. Has an systolic blood pressure greater than 180 mmHg or diastolic blood pressuregreater than 114 mmHg at Randomization.

2. Is taking or expected to take an excluded medication including antihypertensiveagents, insulin or other agents that alter blood pressure.

3. Is hypersensitive to angiotensin II receptor blockers and/or angiotensin-convertingenzyme inhibitors.

4. Has a recent history within the last 6 months of myocardial infarction, heartfailure, unstable angina, coronary artery bypass graft, percutaneous coronaryintervention, hypertensive encephalopathy, cerebrovascular accident, or transientischemic attack.

5. Has clinically significant cardiac conduction defects (eg, third-degreeatrioventricular block, left bundle branch block, sick sinus syndrome, atrialfibrillation or flutter).

6. Has hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

7. Has secondary hypertension of any etiology (eg, renovascular disease,pheochromocytoma, Cushing's syndrome).

8. Is noncompliant (less than 70% or greater than 130%) with study medication duringplacebo run-in period.

9. Has severe renal dysfunction or disease (based on calculated creatinine clearanceless than 30 mL/min/1.73 m at Screening).

10. Has known or suspected unilateral or bilateral renal artery stenosis.

11. Has a history of drug or alcohol abuse within the past 2 years.

12. Has a previous history of cancer that has not been in remission for at least 5 yearsprior to the first dose of study drug. (This criterion does not apply to thoseparticipants with basal cell or stage I squamous cell carcinoma of the skin).

13. Has type 1 or poorly controlled type 2 diabetes mellitus (hemoglobin A1c greater than8.0%) or is taking insulin.

14. Has hyperkalemia as defined by the central laboratory normal reference range atScreening.

15. Has an upper arm circumference less than 24 cm or greater than 42 cm.

16. Works night (third) shift (defined as 11 PM to 7 AM).

17. Has an alanine aminotransferase level at Screening of greater than 2.5 times theupper limit of normal, active liver disease, or jaundice.

18. Is currently participating in another investigational study or has participated in aninvestigational study within 30 days prior to Screening.

19. Has any other serious disease or condition at Screening or Randomization that wouldcompromise participant's safety, might affect life expectancy, or make it difficultto successfully manage and follow the participant according to the protocol.

20. Has been randomized in a previous azilsartan medoxomil study.</note>
                    </notes>
                </inclusion>
                <exclusion>
                    <value>1. Has an systolic blood pressure greater than 180 mmHg or diastolic blood pressuregreater than 114 mmHg at Randomization.

2. Is taking or expected to take an excluded medication including antihypertensiveagents, insulin or other agents that alter blood pressure.

3. Is hypersensitive to angiotensin II receptor blockers and/or angiotensin-convertingenzyme inhibitors.

4. Has a recent history within the last 6 months of myocardial infarction, heartfailure, unstable angina, coronary artery bypass graft, percutaneous coronaryintervention, hypertensive encephalopathy, cerebrovascular accident, or transientischemic attack.

5. Has clinically significant cardiac conduction defects (eg, third-degreeatrioventricular block, left bundle branch block, sick sinus syndrome, atrialfibrillation or flutter).

6. Has hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

7. Has secondary hypertension of any etiology (eg, renovascular disease,pheochromocytoma, Cushing's syndrome).

8. Is noncompliant (less than 70% or greater than 130%) with study medication duringplacebo run-in period.

9. Has severe renal dysfunction or disease (based on calculated creatinine clearanceless than 30 mL/min/1.73 m at Screening).

10. Has known or suspected unilateral or bilateral renal artery stenosis.

11. Has a history of drug or alcohol abuse within the past 2 years.

12. Has a previous history of cancer that has not been in remission for at least 5 yearsprior to the first dose of study drug. (This criterion does not apply to thoseparticipants with basal cell or stage I squamous cell carcinoma of the skin).

13. Has type 1 or poorly controlled type 2 diabetes mellitus (hemoglobin A1c greater than8.0%) or is taking insulin.

14. Has hyperkalemia as defined by the central laboratory normal reference range atScreening.

15. Has an upper arm circumference less than 24 cm or greater than 42 cm.

16. Works night (third) shift (defined as 11 PM to 7 AM).

17. Has an alanine aminotransferase level at Screening of greater than 2.5 times theupper limit of normal, active liver disease, or jaundice.

18. Is currently participating in another investigational study or has participated in aninvestigational study within 30 days prior to Screening.

19. Has any other serious disease or condition at Screening or Randomization that wouldcompromise participant's safety, might affect life expectancy, or make it difficultto successfully manage and follow the participant according to the protocol.

20. Has been randomized in a previous azilsartan medoxomil study.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria:

1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg,inclusive).

2. A female participant of childbearing potential who is sexually active agrees to useadequate contraception from screening throughout the duration of the study, andcannot be pregnant.

3. Has clinical laboratory evaluations (including clinical chemistry, hematology, andcomplete urinalysis) within the reference range for the testing laboratory atScreening or the results are deemed not clinically significant for inclusion intothis study by the investigator.

4. Is willing to discontinue current antihypertensive medications at Screening Day -21.If the participant is on amlodipine prior to screening, the participant is willing todiscontinue this medication at Screening Day -28.

Exclusion Criteria:

1. Has an systolic blood pressure greater than 180 mmHg or diastolic blood pressuregreater than 114 mmHg at Randomization.

2. Is taking or expected to take an excluded medication including antihypertensiveagents, insulin or other agents that alter blood pressure.

3. Is hypersensitive to angiotensin II receptor blockers and/or angiotensin-convertingenzyme inhibitors.

4. Has a recent history within the last 6 months of myocardial infarction, heartfailure, unstable angina, coronary artery bypass graft, percutaneous coronaryintervention, hypertensive encephalopathy, cerebrovascular accident, or transientischemic attack.

5. Has clinically significant cardiac conduction defects (eg, third-degreeatrioventricular block, left bundle branch block, sick sinus syndrome, atrialfibrillation or flutter).

6. Has hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

7. Has secondary hypertension of any etiology (eg, renovascular disease,pheochromocytoma, Cushing's syndrome).

8. Is noncompliant (less than 70% or greater than 130%) with study medication duringplacebo run-in period.

9. Has severe renal dysfunction or disease (based on calculated creatinine clearanceless than 30 mL/min/1.73 m at Screening).

10. Has known or suspected unilateral or bilateral renal artery stenosis.

11. Has a history of drug or alcohol abuse within the past 2 years.

12. Has a previous history of cancer that has not been in remission for at least 5 yearsprior to the first dose of study drug. (This criterion does not apply to thoseparticipants with basal cell or stage I squamous cell carcinoma of the skin).

13. Has type 1 or poorly controlled type 2 diabetes mellitus (hemoglobin A1c greater than8.0%) or is taking insulin.

14. Has hyperkalemia as defined by the central laboratory normal reference range atScreening.

15. Has an upper arm circumference less than 24 cm or greater than 42 cm.

16. Works night (third) shift (defined as 11 PM to 7 AM).

17. Has an alanine aminotransferase level at Screening of greater than 2.5 times theupper limit of normal, active liver disease, or jaundice.

18. Is currently participating in another investigational study or has participated in aninvestigational study within 30 days prior to Screening.

19. Has any other serious disease or condition at Screening or Randomization that wouldcompromise participant's safety, might affect life expectancy, or make it difficultto successfully manage and follow the participant according to the protocol.

20. Has been randomized in a previous azilsartan medoxomil study.</note>
                    </notes>
                </exclusion>
                <references/>
                <source>
                    <value>CLINICALTRIALS</value>
                    <notes>
                        <note source="CLINICALTRIALS">http://clinicaltrials.gov/show/NCT00760214</note>
                    </notes>
                </source>
                <creation_date>
                    <value>2012-09-24</value>
                    <notes>
                        <note source="CLINICALTRIALS">Information obtained from ClinicalTrials.gov on September 20, 2012</note>
                    </notes>
                </creation_date>
            </characteristics>
            <studyOutcomeMeasures>
                <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)" primary="true">
                    <endpoint name="SBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
Description: The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 24 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 24.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="DBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
Description: The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 24 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
Time frame: Baseline and Week 24.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP 24-hour mean" primary="false">
                    <endpoint name="SBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 24.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 24-hour mean" primary="false">
                    <endpoint name="DBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in 24-hour mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline and Week 24.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP 12-hour mean" primary="false">
                    <endpoint name="SBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
Description: The change in the 12-hour mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 24.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 12-hour mean" primary="false">
                    <endpoint name="DBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
Description: The change in the 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline and Week 24.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP daytime mean" primary="false">
                    <endpoint name="SBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 24.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP daytime mean" primary="false">
                    <endpoint name="DBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline and Week 24.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP nighttime mean" primary="false">
                    <endpoint name="SBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 24.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP nighttime mean" primary="false">
                    <endpoint name="DBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline and Week 24.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP trough mean" primary="false">
                    <endpoint name="SBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 24.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP trough mean" primary="false">
                    <endpoint name="DBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline and Week 24.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-SAE" primary="false">
                    <adverseEvent name="SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, serious adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation" primary="false">
                    <adverseEvent name="Atrial fibrillation"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Atrial fibrillation (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Acute coronary syndrome" primary="false">
                    <adverseEvent name="Acute coronary syndrome"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Acute coronary syndrome (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Angina pectoris" primary="false">
                    <adverseEvent name="Angina pectoris"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Angina pectoris (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Hydrocele" primary="false">
                    <adverseEvent name="Hydrocele"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Hydrocele (Congenital, familial and genetic disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cataract" primary="false">
                    <adverseEvent name="Cataract"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cataract (Eye disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Retinal detachment" primary="false">
                    <adverseEvent name="Retinal detachment"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Retinal detachment (Eye disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Salivary gland calculus" primary="false">
                    <adverseEvent name="Salivary gland calculus"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Salivary gland calculus (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Appendicitis" primary="false">
                    <adverseEvent name="Appendicitis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Appendicitis (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Hepatitis C" primary="false">
                    <adverseEvent name="Hepatitis C"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Hepatitis C (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Urosepsis" primary="false">
                    <adverseEvent name="Urosepsis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Urosepsis (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection" primary="false">
                    <adverseEvent name="Upper respiratory tract infection"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Upper respiratory tract infection (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Ankle fracture" primary="false">
                    <adverseEvent name="Ankle fracture"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Ankle fracture (Injury, poisoning and procedural complications)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Fall" primary="false">
                    <adverseEvent name="Fall"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Fall (Injury, poisoning and procedural complications)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Road traffic accident" primary="false">
                    <adverseEvent name="Road traffic accident"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Road traffic accident (Injury, poisoning and procedural complications)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Hyperkalaemia" primary="false">
                    <adverseEvent name="Hyperkalaemia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Hyperkalaemia (Metabolism and nutrition disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Lung neoplasm malignant" primary="false">
                    <adverseEvent name="Lung neoplasm malignant"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Lung neoplasm malignant (Neoplasms benign, malignant and unspecified (incl cysts and polyps))</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Renal cancer" primary="false">
                    <adverseEvent name="Renal cancer"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Renal cancer (Neoplasms benign, malignant and unspecified (incl cysts and polyps))</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cerebral ischaemia" primary="false">
                    <adverseEvent name="Cerebral ischaemia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cerebral ischaemia (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Epilepsy" primary="false">
                    <adverseEvent name="Epilepsy"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Epilepsy (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Grand mal convulsion" primary="false">
                    <adverseEvent name="Grand mal convulsion"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Grand mal convulsion (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke" primary="false">
                    <adverseEvent name="Ischaemic stroke"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Ischaemic stroke (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Syncope" primary="false">
                    <adverseEvent name="Syncope"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Syncope (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Laryngeal oedema" primary="false">
                    <adverseEvent name="Laryngeal oedema"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Laryngeal oedema (Respiratory, thoracic and mediastinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Non-SAE" primary="false">
                    <adverseEvent name="Non-SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, other adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis" primary="false">
                    <adverseEvent name="Nasopharyngitis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Nasopharyngitis (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cough" primary="false">
                    <adverseEvent name="Cough"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cough (Respiratory, thoracic and mediastinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)" primary="false">
                    <populationCharacteristic name="Age (cut-off 45, 65)"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Age
Units: Participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Gender" primary="false">
                    <populationCharacteristic name="Gender"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gender
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
            </studyOutcomeMeasures>
            <arms>
                <arm name="Azilsartan Medoxomil 40 mg QD" size="295">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 40 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.</note>
                    </notes>
                </arm>
                <arm name="Azilsartan Medoxomil 80 mg QD" size="294">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 80 mg QD
Arm Type: Experimental

Intervention Name: Azilsartan medoxomil
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.</note>
                    </notes>
                </arm>
                <arm name="Ramipril 10 mg QD" size="295">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Ramipril 10 mg QD
Arm Type: Active Comparator

Intervention Name: Ramipril
Intervention Type: Drug
Intervention Description: Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.</note>
                    </notes>
                </arm>
            </arms>
            <measurements>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.71" sampleSize="131" stdDev="8.504023694698882"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.07" sampleSize="135" stdDev="8.505071428271487"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <continuousMeasurement mean="-5.65" sampleSize="127" stdDev="8.508417890536407"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.03" sampleSize="131" stdDev="7.496817658180037"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.32" sampleSize="135" stdDev="7.505841724949974"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <continuousMeasurement mean="-5.26" sampleSize="127" stdDev="7.505438827943373"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-8.19" sampleSize="131" stdDev="8.011866199581718"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.53" sampleSize="135" stdDev="8.00545657661073"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <continuousMeasurement mean="-5.55" sampleSize="127" stdDev="8.012563073074682"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-10.18" sampleSize="291" stdDev="9.433473326405286"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-10.54" sampleSize="289" stdDev="9.452000000000002"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <continuousMeasurement mean="-4.87" sampleSize="290" stdDev="9.451309433089154"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-7.44" sampleSize="130" stdDev="8.710940247757414"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-8.2" sampleSize="135" stdDev="8.714212528966687"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <continuousMeasurement mean="-4.43" sampleSize="127" stdDev="8.71126758858893"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-10.21" sampleSize="130" stdDev="10.238775317390258"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-9.85" sampleSize="135" stdDev="10.259532884103447"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <continuousMeasurement mean="-4.53" sampleSize="127" stdDev="10.243909751652442"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.06" sampleSize="131" stdDev="12.624412025912337"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-11.71" sampleSize="135" stdDev="12.629798691982385"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <continuousMeasurement mean="-8.28" sampleSize="127" stdDev="12.633028417604386"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.65" sampleSize="131" stdDev="11.514196281113156"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-12.29" sampleSize="135" stdDev="11.525998438313271"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <continuousMeasurement mean="-7.83" sampleSize="127" stdDev="11.517355078315507"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.61" sampleSize="131" stdDev="11.983462729945797"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-12.35" sampleSize="135" stdDev="11.990756439858162"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <continuousMeasurement mean="-8.08" sampleSize="127" stdDev="11.990671040438063"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-20.63" sampleSize="291" stdDev="16.13755111533345"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-21.24" sampleSize="289" stdDev="16.133"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <continuousMeasurement mean="-12.22" sampleSize="290" stdDev="16.14385827489823"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-12.82" sampleSize="130" stdDev="12.940991074875216"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-12.69" sampleSize="135" stdDev="12.95512929306381"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <continuousMeasurement mean="-6.87" sampleSize="127" stdDev="12.926033537013588"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <continuousMeasurement mean="-15.6" sampleSize="130" stdDev="13.362855982161896"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <continuousMeasurement mean="-14.93" sampleSize="135" stdDev="13.37341149445421"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <continuousMeasurement mean="-6.73" sampleSize="127" stdDev="13.365541216127387"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Acute coronary syndrome"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Acute coronary syndrome"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Acute coronary syndrome"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Angina pectoris"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Angina pectoris"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Angina pectoris"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ankle fracture"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ankle fracture"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ankle fracture"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Appendicitis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Appendicitis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Appendicitis"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="2" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Atrial fibrillation"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cataract"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cataract"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cataract"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cerebral ischaemia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cerebral ischaemia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cerebral ischaemia"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cough"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="3" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cough"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="4" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cough"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="24" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epilepsy"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Fall"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Fall"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Fall"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Grand mal convulsion"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Grand mal convulsion"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Grand mal convulsion"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Hepatitis C"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Hepatitis C"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Hepatitis C"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Hydrocele"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Hydrocele"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Hydrocele"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Hyperkalaemia"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Hyperkalaemia"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Hyperkalaemia"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Ischaemic stroke"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Laryngeal oedema"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Laryngeal oedema"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Laryngeal oedema"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lung neoplasm malignant"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lung neoplasm malignant"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Lung neoplasm malignant"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="19" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="13" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Nasopharyngitis"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="17" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="22" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="16" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="36" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Renal cancer"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Renal cancer"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Renal cancer"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Retinal detachment"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Retinal detachment"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Retinal detachment"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Road traffic accident"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Road traffic accident"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Road traffic accident"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="8" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="12" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="6" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Salivary gland calculus"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Salivary gland calculus"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Salivary gland calculus"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Syncope"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Syncope"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Syncope"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Upper respiratory tract infection"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Urosepsis"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="294"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Urosepsis"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Urosepsis"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="293"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="115"/>
                        <category name="45-64" rate="529"/>
                        <category name="&gt; 64" rate="240"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="40"/>
                        <category name="45-64" rate="166"/>
                        <category name="&gt; 64" rate="89"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="45"/>
                        <category name="45-64" rate="168"/>
                        <category name="&gt; 64" rate="81"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="30"/>
                        <category name="45-64" rate="195"/>
                        <category name="&gt; 64" rate="70"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="421"/>
                        <category name="Male" rate="463"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="136"/>
                        <category name="Male" rate="159"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="136"/>
                        <category name="Male" rate="158"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Ramipril 10 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="149"/>
                        <category name="Male" rate="146"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
            </measurements>
            <epochs>
                <epoch name="Randomization">
                    <notes/>
                </epoch>
                <epoch name="Main phase">
                    <duration>P168D</duration>
                    <notes/>
                </epoch>
            </epochs>
            <activities>
                <studyActivity name="Randomization">
                    <activity>
                        <predefined>RANDOMIZATION</predefined>
                    </activity>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <usedBy epoch="Randomization" arm="Ramipril 10 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 40">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="20.0" maxDose="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 40 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan medoxomil 1">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="20.0" maxDose="80.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 80 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Ramipril">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="2.5" maxDose="10.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Ramipril"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Ramipril 10 mg QD"/>
                    <notes/>
                </studyActivity>
            </activities>
            <notes>
                <note source="CLINICALTRIALS">NCT00760214</note>
                <note source="MANUAL">This is one of the "main studies" supporting the Edarbi application for monotherapy identified in the EMA EPAR available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002293/WC500119206.pdf

Retrieved from ClinicalTrials.gov using the Takeda internal study identifier 491-020.</note>
            </notes>
        </study>
        <study name="TAK491-301 / NCT00846365">
            <indication name="Hypertensive disorder">
                <notes>
                    <note source="CLINICALTRIALS">Essential Hypertension</note>
                </notes>
            </indication>
            <characteristics>
                <title>
                    <value>Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension</value>
                    <notes>
                        <note source="CLINICALTRIALS">Brief title: Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

Official title: A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCT (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension</note>
                    </notes>
                </title>
                <allocation>
                    <value>RANDOMIZED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </allocation>
                <blinding>
                    <value>DOUBLE_BLIND</value>
                    <notes>
                        <note source="CLINICALTRIALS">Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</note>
                    </notes>
                </blinding>
                <centers>
                    <value>80</value>
                    <notes>
                        <note source="CLINICALTRIALS">Birmingham, Alabama, United States
Haleyville, Alabama, United States
Hueytown, Alabama, United States
Jasper, Alabama, United States
Tallassee, Alabama, United States
Green Valley, Arizona, United States
Phoenix, Arizona, United States
Long Beach, California, United States
National City, California, United States
Roseville, California, United States
San Francisco, California, United States
San Jose, California, United States
Newark, Delaware, United States
Clearwater, Florida, United States
Jacksonville, Florida, United States
Jupiter, Florida, United States
Miami, Florida, United States
Ocala, Florida, United States
Pembroke Pines, Florida, United States
Plant City, Florida, United States
Tallahassee, Florida, United States
Arlington Heights, Illinois, United States
Chicago, Illinois, United States
Gurnee, Illinois, United States
Avon, Indiana, United States
Wichita, Kansas, United States
Louisville, Kentucky, United States
Auburn, Maine, United States
Baltimore, Maryland, United States
Brockton, Massachusetts, United States
Haverhill, Massachusetts, United States
North Dartmouth, Massachusetts, United States
Bingham Farms, Michigan, United States
Stevensville, Michigan, United States
Olive Branch, Mississippi, United States
Kansas City, Missouri, United States
New York, New York, United States
Burlington, North Carolina, United States
Charlotte, North Carolina, United States
Hickory, North Carolina, United States
Shelby, North Carolina, United States
Akron, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Marion, Ohio, United States
Middleburg Heights, Ohio, United States
Willoughby Hills, Ohio, United States
Norman, Oklahoma, United States
Bensalem, Pennsylvania, United States
Erie, Pennsylvania, United States
Reading, Pennsylvania, United States
Cranston, Rhode Island, United States
Cumberland, Rhode Island, United States
North Charleston, South Carolina, United States
Jackson, Tennessee, United States
Kingsport, Tennessee, United States
Milan, Tennessee, United States
Austin, Texas, United States
Corpus Christi, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
Arlington, Virginia, United States
Burke, Virginia, United States
Charlottesville, Virginia, United States
Manassas, Virginia, United States
Lakewood, Washington, United States
Port Orchard, Washington, United States
Menomonee Falls, Wisconsin, United States
Temuco, Cautn, Chile
La Serena, Elqui, Chile
Vina del Mar, Valparaso, Chile
Osorno, Chile
Santiago, Chile
Tijuana, Baja California, Mexico
Leon, Guanajuato, Mexico
Guadalajara, Jalisco, Mexico
Chihuahua, Mexico
San Luis Potosi, Mexico
</note>
                    </notes>
                </centers>
                <objective>
                    <value>The purpose of this study is to determine the efficacy and safety of azilsartan medoxomilcombined with chlorthalidone, once daily (QD), in participants with moderate to severeessential hypertension.</value>
                    <notes>
                        <note source="CLINICALTRIALS">The purpose of this study is to determine the efficacy and safety of azilsartan medoxomilcombined with chlorthalidone, once daily (QD), in participants with moderate to severeessential hypertension.</note>
                    </notes>
                </objective>
                <study_start>
                    <value>2009-03-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">March 2009</note>
                    </notes>
                </study_start>
                <study_end>
                    <value>2010-06-01</value>
                    <notes>
                        <note source="CLINICALTRIALS">June 2010</note>
                    </notes>
                </study_end>
                <status>
                    <value>COMPLETED</value>
                    <notes>
                        <note source="CLINICALTRIALS">Completed</note>
                    </notes>
                </status>
                <inclusion>
                    <value>1. 190 mm Hg on Day -1 or if the participant has not received antihypertensive treatmentwithin 28 days before screening and has a mean sitting clinic systolic blood pressuregreater than or equal to 160 and less than or equal to 190 mm Hg at the ScreeningVisit and on Day -1.

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Has clinical laboratory test results within the reference range for the testinglaboratory or the investigator does not consider the results to be clinicallysignificant.

4. Is willing to discontinue current antihypertensive medications on Day -21 or on Day-28 if is on amlodipine or chlorthalidone.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria:

1. 190 mm Hg on Day -1 or if the participant has not received antihypertensive treatmentwithin 28 days before screening and has a mean sitting clinic systolic blood pressuregreater than or equal to 160 and less than or equal to 190 mm Hg at the ScreeningVisit and on Day -1.

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Has clinical laboratory test results within the reference range for the testinglaboratory or the investigator does not consider the results to be clinicallysignificant.

4. Is willing to discontinue current antihypertensive medications on Day -21 or on Day-28 if is on amlodipine or chlorthalidone.

Exclusion Criteria:

1. Has a mean sitting clinic diastolic blood pressure greater than 119 mm Hg.

2. Has a baseline 24-hour ambulatory blood pressure monitoring reading of insufficientquality.

3. Works a night (third) shift (from 11 PM [2300] to 7 AM [0700]).

4. Has an upper arm circumference less than 24 cm or greater than 42 cm.

5. Is noncompliant with study medication during the placebo run-in period.

6. Has secondary hypertension of any etiology.

7. Has a recent history of myocardial infarction, heart failure, unstable angina,coronary artery bypass graft, percutaneous coronary intervention, hypertensiveencephalopathy, cerebrovascular accident or transient ischemic attack.

8. Has a clinically significant cardiac conduction.

9. Has hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

10. Has severe renal dysfunction or disease.

11. Has a known or suspected unilateral or bilateral renal artery stenosis.

12. Has a history of cancer that has not been in remission for at least 5 years prior tothe first dose of study drug.

13. Has poorly controlled type 1 or type 2 diabetes mellitus.

14. Has hypokalemia or hyperkalemia.

15. Has an alanine aminotransferase or aspartate aminotransferase level of greater than2.5 times the upper limit of normal, active liver disease or jaundice.

16. Has any other known serious disease or condition that would compromise safety, mightaffect life expectancy or make it difficult to successfully manage and follow theparticipant according to the protocol.

17. Has a known hypersensitivity to angiotensin II receptor blockers or thiazide-typediuretics or other sulfonamide-derived compounds.

18. Has been randomized in a previous Azilsartan Medoxomil study.

19. Is currently participating in another investigational study or has participated in aninvestigational study or is receiving or has received any investigational compoundwithin 30 days prior to Randomization.

20. Has a history of drug abuse or a history of alcohol abuse within the past 2 years.</note>
                    </notes>
                </inclusion>
                <exclusion>
                    <value>1. Has a mean sitting clinic diastolic blood pressure greater than 119 mm Hg.

2. Has a baseline 24-hour ambulatory blood pressure monitoring reading of insufficientquality.

3. Works a night (third) shift (from 11 PM [2300] to 7 AM [0700]).

4. Has an upper arm circumference less than 24 cm or greater than 42 cm.

5. Is noncompliant with study medication during the placebo run-in period.

6. Has secondary hypertension of any etiology.

7. Has a recent history of myocardial infarction, heart failure, unstable angina,coronary artery bypass graft, percutaneous coronary intervention, hypertensiveencephalopathy, cerebrovascular accident or transient ischemic attack.

8. Has a clinically significant cardiac conduction.

9. Has hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

10. Has severe renal dysfunction or disease.

11. Has a known or suspected unilateral or bilateral renal artery stenosis.

12. Has a history of cancer that has not been in remission for at least 5 years prior tothe first dose of study drug.

13. Has poorly controlled type 1 or type 2 diabetes mellitus.

14. Has hypokalemia or hyperkalemia.

15. Has an alanine aminotransferase or aspartate aminotransferase level of greater than2.5 times the upper limit of normal, active liver disease or jaundice.

16. Has any other known serious disease or condition that would compromise safety, mightaffect life expectancy or make it difficult to successfully manage and follow theparticipant according to the protocol.

17. Has a known hypersensitivity to angiotensin II receptor blockers or thiazide-typediuretics or other sulfonamide-derived compounds.

18. Has been randomized in a previous Azilsartan Medoxomil study.

19. Is currently participating in another investigational study or has participated in aninvestigational study or is receiving or has received any investigational compoundwithin 30 days prior to Randomization.

20. Has a history of drug abuse or a history of alcohol abuse within the past 2 years.</value>
                    <notes>
                        <note source="CLINICALTRIALS">Inclusion Criteria:

1. 190 mm Hg on Day -1 or if the participant has not received antihypertensive treatmentwithin 28 days before screening and has a mean sitting clinic systolic blood pressuregreater than or equal to 160 and less than or equal to 190 mm Hg at the ScreeningVisit and on Day -1.

2. Females of childbearing potential who are sexually active must agree to use adequatecontraception, and can neither be pregnant nor lactating from Screening throughoutthe duration of the study.

3. Has clinical laboratory test results within the reference range for the testinglaboratory or the investigator does not consider the results to be clinicallysignificant.

4. Is willing to discontinue current antihypertensive medications on Day -21 or on Day-28 if is on amlodipine or chlorthalidone.

Exclusion Criteria:

1. Has a mean sitting clinic diastolic blood pressure greater than 119 mm Hg.

2. Has a baseline 24-hour ambulatory blood pressure monitoring reading of insufficientquality.

3. Works a night (third) shift (from 11 PM [2300] to 7 AM [0700]).

4. Has an upper arm circumference less than 24 cm or greater than 42 cm.

5. Is noncompliant with study medication during the placebo run-in period.

6. Has secondary hypertension of any etiology.

7. Has a recent history of myocardial infarction, heart failure, unstable angina,coronary artery bypass graft, percutaneous coronary intervention, hypertensiveencephalopathy, cerebrovascular accident or transient ischemic attack.

8. Has a clinically significant cardiac conduction.

9. Has hemodynamically significant left ventricular outflow obstruction due to aorticvalvular disease.

10. Has severe renal dysfunction or disease.

11. Has a known or suspected unilateral or bilateral renal artery stenosis.

12. Has a history of cancer that has not been in remission for at least 5 years prior tothe first dose of study drug.

13. Has poorly controlled type 1 or type 2 diabetes mellitus.

14. Has hypokalemia or hyperkalemia.

15. Has an alanine aminotransferase or aspartate aminotransferase level of greater than2.5 times the upper limit of normal, active liver disease or jaundice.

16. Has any other known serious disease or condition that would compromise safety, mightaffect life expectancy or make it difficult to successfully manage and follow theparticipant according to the protocol.

17. Has a known hypersensitivity to angiotensin II receptor blockers or thiazide-typediuretics or other sulfonamide-derived compounds.

18. Has been randomized in a previous Azilsartan Medoxomil study.

19. Is currently participating in another investigational study or has participated in aninvestigational study or is receiving or has received any investigational compoundwithin 30 days prior to Randomization.

20. Has a history of drug abuse or a history of alcohol abuse within the past 2 years.</note>
                    </notes>
                </exclusion>
                <references/>
                <source>
                    <value>CLINICALTRIALS</value>
                    <notes>
                        <note source="CLINICALTRIALS">http://clinicaltrials.gov/show/NCT00846365</note>
                    </notes>
                </source>
                <creation_date>
                    <value>2012-09-24</value>
                    <notes>
                        <note source="CLINICALTRIALS">Information obtained from ClinicalTrials.gov on September 20, 2012</note>
                    </notes>
                </creation_date>
            </characteristics>
            <studyOutcomeMeasures>
                <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)" primary="true">
                    <endpoint name="SBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.
Description: The change in trough systolic blood pressure measured at week 8 or final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.
Time frame: Baseline and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)" primary="false">
                    <endpoint name="DBP mean trough (clinic, sitting)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure
Description: The change in trough diastolic blood pressure measured at week 4 and week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements.
Time frame: Baseline, Week 4 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP trough mean" primary="false">
                    <endpoint name="SBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Trough Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline, Week 4 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP trough mean" primary="false">
                    <endpoint name="DBP trough mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Trough Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline, Week 4 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP 24-hour mean" primary="false">
                    <endpoint name="SBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in the 24-hour mean  systolic blood pressure at week4  and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline, Week 4 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 24-hour mean" primary="false">
                    <endpoint name="DBP 24-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in the 0 to 24-hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. . Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average  of measurements collected over the subsequent 24 hours.
Time frame: Baseline, Week 4 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP daytime mean" primary="false">
                    <endpoint name="SBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime Mean (6am to 10pm) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in the daytime, while awake (6am to 10pm) mean systolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations.
Time frame: Baseline, Week 4 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP daytime mean" primary="false">
                    <endpoint name="DBP daytime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Daytime Mean (6am to 10pm) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in the daytime, while awake (6am to 10pm) mean diastolic blood pressure measured at Week 4 and Week 8relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations.
Time frame: Baseline, Week 4 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP nighttime mean" primary="false">
                    <endpoint name="SBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Nighttime Mean (12am to 6am) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
Description: The change in the nighttime, while asleep (12am to 6am) mean systolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average  of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations.
Time frame: Baseline, Week 4 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP nighttime mean" primary="false">
                    <endpoint name="DBP nighttime mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in Nighttime Mean (12am to 6am) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in the nighttime, while asleep (12am to 6am) mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations.
Time frame: Baseline, Week 4 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP 12-hour mean" primary="false">
                    <endpoint name="SBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in the 0 to 12 hours-after-dosing mean Systolic Blood Pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours.
Time frame: Baseline, Week 4 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP 12-hour mean" primary="false">
                    <endpoint name="DBP 12-hour mean"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Change From Baseline in 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
Description: The change in the 0 to 12 hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours.
Time frame: Baseline, Week 4 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP response (clinic)" primary="false">
                    <endpoint name="SBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P14D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P42D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as &lt;140 mm Hg for Participants Without Diabetes or CKD or &lt;130 mm Hg for Participants With Diabetes or CKD
Description: Percentage of participants who achieve a clinic systolic blood pressure response, defined as &lt;140 mm Hg for participants without diabetes or CKD or &lt;130 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.
Time frame: Baseline, Week 2, Week 4, Week 6 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-DBP response (clinic)" primary="false">
                    <endpoint name="DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P14D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P42D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as Defined as &lt;90 mm Hg for Participants Without Diabetes or CKD or &lt;80 mm Hg for Participants With Diabetes or CKD
Description: Percentage of participants who achieve a clinic diastolic blood pressure response, defined as defined as &lt;90 mm Hg for participants without diabetes or CKD or &lt;80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.
Time frame: Baseline, Week 2, Week 4, Week 6 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)" primary="false">
                    <endpoint name="SBP and DBP response (clinic)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P14D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <whenTaken howLong="P42D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Percentage of Participants Who Achieve a Clinic Diastolic AND Systolic Blood Pressure Response, Defined as &lt;140/90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease (CKD) or &lt;130/80 mm Hg for Participants With Diabetes or CKD
Description: Percentage of participants who achieve both a clinic diastolic blood pressure response, defined as &lt;140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) or &lt;130/80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.
Time frame: Baseline, Week 2, Week 4, Week 6 and Week 8.
Safety issue: No</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-SAE" primary="false">
                    <adverseEvent name="SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, serious adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cardiac arrest" primary="false">
                    <adverseEvent name="Cardiac arrest"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cardiac arrest (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Coronary artery disease" primary="false">
                    <adverseEvent name="Coronary artery disease"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Coronary artery disease (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Diastolic dysfunction" primary="false">
                    <adverseEvent name="Diastolic dysfunction"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Diastolic dysfunction (Cardiac disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Diarrhoea" primary="false">
                    <adverseEvent name="Diarrhoea"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Diarrhoea (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Epigastric discomfort" primary="false">
                    <adverseEvent name="Epigastric discomfort"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Epigastric discomfort (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Nausea" primary="false">
                    <adverseEvent name="Nausea"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Nausea (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Pancreatitis" primary="false">
                    <adverseEvent name="Pancreatitis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Pancreatitis (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Vomiting" primary="false">
                    <adverseEvent name="Vomiting"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Vomiting (Gastrointestinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Chest pain" primary="false">
                    <adverseEvent name="Chest pain"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Chest pain (General disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Generalised oedema" primary="false">
                    <adverseEvent name="Generalised oedema"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Generalised oedema (General disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Systemic inflammatory response syndrome" primary="false">
                    <adverseEvent name="Systemic inflammatory response syndrome"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Systemic inflammatory response syndrome (General disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cellulitis" primary="false">
                    <adverseEvent name="Cellulitis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cellulitis (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Gastroenteritis" primary="false">
                    <adverseEvent name="Gastroenteritis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gastroenteritis (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Pneumonia" primary="false">
                    <adverseEvent name="Pneumonia"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Pneumonia (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Viral infection" primary="false">
                    <adverseEvent name="Viral infection"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Viral infection (Infections and infestations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Heat exhaustion" primary="false">
                    <adverseEvent name="Heat exhaustion"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Heat exhaustion (Injury, poisoning and procedural complications)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Road traffic accident" primary="false">
                    <adverseEvent name="Road traffic accident"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Road traffic accident (Injury, poisoning and procedural complications)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Blood creatinine increased" primary="false">
                    <adverseEvent name="Blood creatinine increased"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Blood creatinine increased (Investigations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Troponin increased" primary="false">
                    <adverseEvent name="Troponin increased"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Troponin increased (Investigations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Dehydration" primary="false">
                    <adverseEvent name="Dehydration"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Dehydration (Metabolism and nutrition disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Cerebral infarction" primary="false">
                    <adverseEvent name="Cerebral infarction"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Cerebral infarction (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Pulmonary embolism" primary="false">
                    <adverseEvent name="Pulmonary embolism"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Pulmonary embolism (Respiratory, thoracic and mediastinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Asthma" primary="false">
                    <adverseEvent name="Asthma"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Asthma (Respiratory, thoracic and mediastinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Sleep apnoea syndrome" primary="false">
                    <adverseEvent name="Sleep apnoea syndrome"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Sleep apnoea syndrome (Respiratory, thoracic and mediastinal disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Angioedema" primary="false">
                    <adverseEvent name="Angioedema"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Angioedema (Skin and subcutaneous tissue disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis" primary="false">
                    <adverseEvent name="Deep vein thrombosis"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Deep vein thrombosis (Vascular disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Shock" primary="false">
                    <adverseEvent name="Shock"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Shock (Vascular disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Non-SAE" primary="false">
                    <adverseEvent name="Non-SAE"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Total, other adverse events (Total)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Blood creatinine increased (non-serious)" primary="false">
                    <adverseEvent name="Blood creatinine increased (non-serious)"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Blood creatinine increased (Investigations)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Dizziness" primary="false">
                    <adverseEvent name="Dizziness"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Dizziness (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="adverseEvent-Headache" primary="false">
                    <adverseEvent name="Headache"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Headache (Nervous system disorders)</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Age" primary="false">
                    <populationCharacteristic name="Age"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Age
Units: years</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)" primary="false">
                    <populationCharacteristic name="Age (cut-off 45, 65)"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Age, Customized
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Gender" primary="false">
                    <populationCharacteristic name="Gender"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Gender
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Ethnicity" primary="false">
                    <populationCharacteristic name="Ethnicity"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Ethnicity (NIH/OMB)
Description: Ethnicity was not collected from Latin American sites.
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Race" primary="false">
                    <populationCharacteristic name="Race"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Race (NIH/OMB)
Description: Participants could choose more than one category for race. Participants who chose more than 1 race category are included in each category indicated and are also included in the multiracial category.
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Region of Enrollment" primary="false">
                    <populationCharacteristic name="Region of Enrollment"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Region of Enrollment
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Weight" primary="false">
                    <populationCharacteristic name="Weight"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Weight
Units: kg</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Height" primary="false">
                    <populationCharacteristic name="Height"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Height
Units: cm</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-BMI" primary="false">
                    <populationCharacteristic name="BMI"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Body Mass Index (BMI)
Description: BMI was calculated using height at Screening and weight at Baseline.
Units: kg/m^2</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-eGFR category" primary="false">
                    <populationCharacteristic name="eGFR category"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Estimated Glomerular Filtration Rate (eGFR) Category
Description: eGFR = creatinine clearance, estimated using the Modification of Diet in Renal Disease equation with the following parameters:
Moderate impairment: 30 to &lt;60 mL/min/1.73 m^2
Mild impairment: 60 to &lt;90 mL/min/1.73 m^2
Normal: 90 mL/min/1.73 m^2
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Chronic Kidney Disease" primary="false">
                    <populationCharacteristic name="Chronic Kidney Disease"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Chronic Kidney Disease (CKD) Status
Description: Participant was considered to have CKD if their eGFR was &lt;60 ml/min/1.73 m^2 or urinary albumin:creatinine ratio was &gt;200 mg albumin/g creatinine at Screening.
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
                <studyOutcomeMeasure id="popChar-Diabetes" primary="false">
                    <populationCharacteristic name="Diabetes"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                    <notes>
                        <note source="CLINICALTRIALS">Diabetes Status
Units: participants</note>
                    </notes>
                </studyOutcomeMeasure>
            </studyOutcomeMeasures>
            <arms>
                <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD" size="372">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD
Arm Type: Experimental
Arm Description: (dependant on blood pressure)

Intervention Name: Azilsartan medoxomil and chlorthalidone
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.</note>
                    </notes>
                </arm>
                <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD" size="357">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD
Arm Type: Experimental
Arm Description: (dependant on blood pressure)

Intervention Name: Azilsartan medoxomil and chlorthalidone
Intervention Type: Drug
Intervention Description: Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo  tablets once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.</note>
                    </notes>
                </arm>
                <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD" size="356">
                    <notes>
                        <note source="CLINICALTRIALS">Arm Name: Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD
Arm Type: Active Comparator
Arm Description: (dependant on blood pressure)

Intervention Name: Olmesartan medoxomil-hydrochlorothiazide
Intervention Type: Drug
Intervention Description: Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg,  tablets, orally,  and Azilsartan medoxomil and chlorthalidone placebo-matching  tablets, orally, once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg,  tablets, orally, once daily for the remaining 4 weeks.</note>
                    </notes>
                </arm>
            </arms>
            <measurements>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-14.4" sampleSize="223" stdDev="8.36"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-15.4" sampleSize="290" stdDev="8.51"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-14.8" sampleSize="227" stdDev="8.29"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-16.9" sampleSize="278" stdDev="8.5"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-10.8" sampleSize="219" stdDev="8.29"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 12-hour mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-12.1" sampleSize="281" stdDev="8.55"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-13.9" sampleSize="223" stdDev="7.62"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-15.1" sampleSize="290" stdDev="7.66"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-14.4" sampleSize="227" stdDev="7.68"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-16.4" sampleSize="278" stdDev="7.67"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-10.5" sampleSize="219" stdDev="7.7"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP 24-hour mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-12.0" sampleSize="281" stdDev="7.71"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-14.2" sampleSize="223" stdDev="7.91"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-15.3" sampleSize="290" stdDev="8.0"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-14.7" sampleSize="227" stdDev="7.99"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-16.6" sampleSize="278" stdDev="8.0"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-10.7" sampleSize="219" stdDev="7.99"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP daytime mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-12.1" sampleSize="281" stdDev="8.05"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-13.6" sampleSize="360" stdDev="0.49"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-16.1" sampleSize="363" stdDev="0.47"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-14.2" sampleSize="347" stdDev="0.5"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-16.5" sampleSize="350" stdDev="0.48"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-10.4" sampleSize="352" stdDev="0.49"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-12.8" sampleSize="353" stdDev="0.48"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-13.4" sampleSize="223" stdDev="8.66"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-14.9" sampleSize="290" stdDev="8.68"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-13.3" sampleSize="227" stdDev="6.74"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-15.8" sampleSize="278" stdDev="8.67"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-9.6" sampleSize="219" stdDev="8.73"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP nighttime mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-11.8" sampleSize="281" stdDev="8.72"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="218" sampleSize="343"/>
                    <whenTaken howLong="P14D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="257" sampleSize="360"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="282" sampleSize="362"/>
                    <whenTaken howLong="P42D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="290" sampleSize="363"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="221" sampleSize="334"/>
                    <whenTaken howLong="P14D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="256" sampleSize="347"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="269" sampleSize="350"/>
                    <whenTaken howLong="P42D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="277" sampleSize="350"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="165" sampleSize="345"/>
                    <whenTaken howLong="P14D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="205" sampleSize="352"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="236" sampleSize="353"/>
                    <whenTaken howLong="P42D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP response (clinic)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="233" sampleSize="353"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-13.4" sampleSize="223" stdDev="9.86"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-14.6" sampleSize="290" stdDev="9.54"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-14.6" sampleSize="227" stdDev="9.94"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-15.9" sampleSize="278" stdDev="9.5"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-10.9" sampleSize="219" stdDev="9.92"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-DBP trough mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-12.0" sampleSize="281" stdDev="9.55"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-25.0" sampleSize="223" stdDev="12.99"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-27.1" sampleSize="290" stdDev="13.11"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-25.5" sampleSize="227" stdDev="12.96"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-28.8" sampleSize="278" stdDev="13.01"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-19.2" sampleSize="219" stdDev="13.02"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 12-hour mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-21.1" sampleSize="281" stdDev="13.08"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-26.4" sampleSize="290" stdDev="11.75"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-24.1" sampleSize="223" stdDev="12.1"/>
                    <whenTaken howLong="P28D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-27.9" sampleSize="278" stdDev="11.67"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-24.4" sampleSize="227" stdDev="12.05"/>
                    <whenTaken howLong="P28D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-20.7" sampleSize="281" stdDev="11.73"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP 24-hour mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-18.4" sampleSize="219" stdDev="11.99"/>
                    <whenTaken howLong="P28D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="176" sampleSize="343"/>
                    <whenTaken howLong="P14D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="209" sampleSize="360"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="249" sampleSize="362"/>
                    <whenTaken howLong="P42D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="252" sampleSize="363"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="162" sampleSize="334"/>
                    <whenTaken howLong="P14D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="213" sampleSize="347"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="229" sampleSize="350"/>
                    <whenTaken howLong="P42D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="241" sampleSize="350"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="124" sampleSize="345"/>
                    <whenTaken howLong="P14D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="157" sampleSize="352"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="196" sampleSize="353"/>
                    <whenTaken howLong="P42D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP and DBP response (clinic)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="193" sampleSize="353"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-26.7" sampleSize="290" stdDev="12.26"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-24.5" sampleSize="223" stdDev="12.54"/>
                    <whenTaken howLong="P28D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-28.4" sampleSize="278" stdDev="12.34"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-25.1" sampleSize="227" stdDev="12.51"/>
                    <whenTaken howLong="P28D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-21.0" sampleSize="281" stdDev="12.4"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP daytime mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-18.9" sampleSize="219" stdDev="12.58"/>
                    <whenTaken howLong="P28D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-33.0" sampleSize="360" stdDev="0.87"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-37.6" sampleSize="363" stdDev="0.83"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-34.1" sampleSize="347" stdDev="0.88"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-38.2" sampleSize="350" stdDev="0.85"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-26.9" sampleSize="352" stdDev="0.88"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP mean trough (clinic, sitting)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-31.5" sampleSize="353" stdDev="0.84"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-22.3" sampleSize="223" stdDev="12.99"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-25.2" sampleSize="290" stdDev="12.6"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-21.9" sampleSize="227" stdDev="12.96"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-26.3" sampleSize="278" stdDev="0.75"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-16.6" sampleSize="219" stdDev="13.02"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP nighttime mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-19.7" sampleSize="281" stdDev="12.57"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="207" sampleSize="343"/>
                    <whenTaken howLong="P14D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="238" sampleSize="360"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="278" sampleSize="362"/>
                    <whenTaken howLong="P42D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="276" sampleSize="363"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="191" sampleSize="334"/>
                    <whenTaken howLong="P14D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="239" sampleSize="347"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="257" sampleSize="350"/>
                    <whenTaken howLong="P42D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="266" sampleSize="350"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="155" sampleSize="345"/>
                    <whenTaken howLong="P14D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="184" sampleSize="352"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="229" sampleSize="353"/>
                    <whenTaken howLong="P42D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP response (clinic)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="228" sampleSize="353"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-22.4" sampleSize="223" stdDev="14.19"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-24.9" sampleSize="290" stdDev="13.45"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-23.6" sampleSize="227" stdDev="14.16"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="-26.8" sampleSize="278" stdDev="13.51"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-17.4" sampleSize="219" stdDev="14.21"/>
                    <whenTaken howLong="P28D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="endpoint-SBP trough mean"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="-19.6" sampleSize="281" stdDev="13.41"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Angioedema"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Angioedema"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Angioedema"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Asthma"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Asthma"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Asthma"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="1" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood creatinine increased"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood creatinine increased"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood creatinine increased"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood creatinine increased (non-serious)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="36" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood creatinine increased (non-serious)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="44" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Blood creatinine increased (non-serious)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="25" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cardiac arrest"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cardiac arrest"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cardiac arrest"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="1" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cellulitis"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="1" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cerebral infarction"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cerebral infarction"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Cerebral infarction"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Chest pain"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="1" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Coronary artery disease"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="1" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Deep vein thrombosis"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="1" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dehydration"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dehydration"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dehydration"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="1" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diarrhoea"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diarrhoea"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diarrhoea"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diastolic dysfunction"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diastolic dysfunction"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Diastolic dysfunction"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="25" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="24" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Dizziness"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="20" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epigastric discomfort"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epigastric discomfort"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Epigastric discomfort"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastroenteritis"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastroenteritis"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Gastroenteritis"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Generalised oedema"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Generalised oedema"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Generalised oedema"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="14" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="14" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Headache"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="18" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Heat exhaustion"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Heat exhaustion"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Heat exhaustion"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="1" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Nausea"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Nausea"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Nausea"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="66" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="72" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Non-SAE"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="56" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pancreatitis"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pancreatitis"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pancreatitis"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pneumonia"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pulmonary embolism"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pulmonary embolism"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Pulmonary embolism"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="1" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Road traffic accident"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Road traffic accident"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Road traffic accident"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="4" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="8" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-SAE"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="6" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Shock"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="1" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Sleep apnoea syndrome"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Sleep apnoea syndrome"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Sleep apnoea syndrome"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Systemic inflammatory response syndrome"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Systemic inflammatory response syndrome"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Systemic inflammatory response syndrome"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="1" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Troponin increased"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Troponin increased"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Troponin increased"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="1" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Viral infection"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Viral infection"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Viral infection"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="1" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="0" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="adverseEvent-Vomiting"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="0" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="BEFORE_EPOCH_END">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age"/>
                    <continuousMeasurement mean="56.0" sampleSize="1085" stdDev="10.38"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="55.5" sampleSize="372" stdDev="10.49"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="56.7" sampleSize="357" stdDev="10.83"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="55.7" sampleSize="356" stdDev="9.78"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="126"/>
                        <category name="45-64" rate="745"/>
                        <category name="&gt; 64" rate="214"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="47"/>
                        <category name="45-64" rate="252"/>
                        <category name="&gt; 64" rate="73"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="38"/>
                        <category name="45-64" rate="244"/>
                        <category name="&gt; 64" rate="75"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Age (cut-off 45, 65)"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <categoricalMeasurement>
                        <category name="&lt; 45" rate="41"/>
                        <category name="45-64" rate="249"/>
                        <category name="&gt; 64" rate="66"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-BMI"/>
                    <continuousMeasurement mean="31.8" sampleSize="1085" stdDev="6.14"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-BMI"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="31.7" sampleSize="372" stdDev="5.94"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-BMI"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="31.8" sampleSize="357" stdDev="6.4"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-BMI"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="31.9" sampleSize="356" stdDev="6.08"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Chronic Kidney Disease"/>
                    <rateMeasurement rate="94" sampleSize="1084"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Chronic Kidney Disease"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="25" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Chronic Kidney Disease"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="41" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Chronic Kidney Disease"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="28" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Diabetes"/>
                    <rateMeasurement rate="188" sampleSize="1085"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Diabetes"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="58" sampleSize="372"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Diabetes"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <rateMeasurement rate="59" sampleSize="357"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Diabetes"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <rateMeasurement rate="71" sampleSize="356"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Ethnicity"/>
                    <categoricalMeasurement>
                        <category name="Hispanic or Latino" rate="122"/>
                        <category name="Not Hispanic or Latino" rate="769"/>
                        <category name="Unknown or Not Reported" rate="194"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Ethnicity"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Hispanic or Latino" rate="37"/>
                        <category name="Not Hispanic or Latino" rate="265"/>
                        <category name="Unknown or Not Reported" rate="70"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Ethnicity"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Hispanic or Latino" rate="41"/>
                        <category name="Not Hispanic or Latino" rate="253"/>
                        <category name="Unknown or Not Reported" rate="63"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Ethnicity"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <categoricalMeasurement>
                        <category name="Hispanic or Latino" rate="44"/>
                        <category name="Not Hispanic or Latino" rate="251"/>
                        <category name="Unknown or Not Reported" rate="61"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="522"/>
                        <category name="Male" rate="563"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="175"/>
                        <category name="Male" rate="197"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="174"/>
                        <category name="Male" rate="183"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Gender"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <categoricalMeasurement>
                        <category name="Female" rate="173"/>
                        <category name="Male" rate="183"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Height"/>
                    <continuousMeasurement mean="167.8" sampleSize="1085" stdDev="10.87"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Height"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="167.5" sampleSize="372" stdDev="11.22"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Height"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="167.8" sampleSize="357" stdDev="11.06"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Height"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="168.2" sampleSize="356" stdDev="10.3"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Race"/>
                    <categoricalMeasurement>
                        <category name="American Indian or Alaska Native" rate="106"/>
                        <category name="Asian" rate="17"/>
                        <category name="Native Hawaiian or Other Pacific Islander" rate="3"/>
                        <category name="Black or African American" rate="290"/>
                        <category name="White" rate="680"/>
                        <category name="More than one race" rate="11"/>
                        <category name="Unknown or Not Reported" rate="0"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Race"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <categoricalMeasurement>
                        <category name="American Indian or Alaska Native" rate="37"/>
                        <category name="Asian" rate="7"/>
                        <category name="Native Hawaiian or Other Pacific Islander" rate="3"/>
                        <category name="Black or African American" rate="95"/>
                        <category name="White" rate="235"/>
                        <category name="More than one race" rate="5"/>
                        <category name="Unknown or Not Reported" rate="0"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Race"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <categoricalMeasurement>
                        <category name="American Indian or Alaska Native" rate="34"/>
                        <category name="Asian" rate="5"/>
                        <category name="Native Hawaiian or Other Pacific Islander" rate="0"/>
                        <category name="Black or African American" rate="95"/>
                        <category name="White" rate="225"/>
                        <category name="More than one race" rate="2"/>
                        <category name="Unknown or Not Reported" rate="0"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Race"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <categoricalMeasurement>
                        <category name="American Indian or Alaska Native" rate="35"/>
                        <category name="Asian" rate="5"/>
                        <category name="Native Hawaiian or Other Pacific Islander" rate="0"/>
                        <category name="Black or African American" rate="100"/>
                        <category name="White" rate="220"/>
                        <category name="More than one race" rate="4"/>
                        <category name="Unknown or Not Reported" rate="0"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Region of Enrollment"/>
                    <categoricalMeasurement>
                        <category name="United States" rate="891"/>
                        <category name="Mexico" rate="132"/>
                        <category name="Chile" rate="31"/>
                        <category name="Argentina" rate="31"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Region of Enrollment"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <categoricalMeasurement>
                        <category name="United States" rate="302"/>
                        <category name="Mexico" rate="45"/>
                        <category name="Chile" rate="12"/>
                        <category name="Argentina" rate="13"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Region of Enrollment"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <categoricalMeasurement>
                        <category name="United States" rate="294"/>
                        <category name="Mexico" rate="44"/>
                        <category name="Chile" rate="10"/>
                        <category name="Argentina" rate="9"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Region of Enrollment"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <categoricalMeasurement>
                        <category name="United States" rate="295"/>
                        <category name="Mexico" rate="43"/>
                        <category name="Chile" rate="9"/>
                        <category name="Argentina" rate="9"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Weight"/>
                    <continuousMeasurement mean="89.95" sampleSize="1085" stdDev="20.981"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Weight"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="89.35" sampleSize="372" stdDev="20.995"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Weight"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <continuousMeasurement mean="89.87" sampleSize="357" stdDev="21.281"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-Weight"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <continuousMeasurement mean="90.66" sampleSize="356" stdDev="20.7"/>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-eGFR category"/>
                    <categoricalMeasurement>
                        <category name="Moderate impairment" rate="76"/>
                        <category name="Mild impairment" rate="632"/>
                        <category name="Normal" rate="377"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-eGFR category"/>
                    <arm name="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Moderate impairment" rate="26"/>
                        <category name="Mild impairment" rate="220"/>
                        <category name="Normal" rate="126"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-eGFR category"/>
                    <arm name="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <categoricalMeasurement>
                        <category name="Moderate impairment" rate="25"/>
                        <category name="Mild impairment" rate="207"/>
                        <category name="Normal" rate="125"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
                <measurement>
                    <studyOutcomeMeasure id="popChar-eGFR category"/>
                    <arm name="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <categoricalMeasurement>
                        <category name="Moderate impairment" rate="25"/>
                        <category name="Mild impairment" rate="205"/>
                        <category name="Normal" rate="126"/>
                    </categoricalMeasurement>
                    <whenTaken howLong="P0D" relativeTo="FROM_EPOCH_START">
                        <epoch name="Main phase"/>
                    </whenTaken>
                </measurement>
            </measurements>
            <epochs>
                <epoch name="Randomization">
                    <notes/>
                </epoch>
                <epoch name="Main phase">
                    <duration>P56D</duration>
                    <notes/>
                </epoch>
            </epochs>
            <activities>
                <studyActivity name="Randomization">
                    <activity>
                        <predefined>RANDOMIZATION</predefined>
                    </activity>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <usedBy epoch="Randomization" arm="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <usedBy epoch="Randomization" arm="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 40 + Chlortalidone">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="20.0" maxDose="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                            <drugTreatment>
<flexibleDose minDose="12.5" maxDose="25.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Chlortalidone"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Azilsartan 80 + Chlorthalidone">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="40.0" maxDose="80.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Azilsartan"/>
                            </drugTreatment>
                            <drugTreatment>
<flexibleDose minDose="12.5" maxDose="25.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Chlortalidone"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD"/>
                    <notes/>
                </studyActivity>
                <studyActivity name="Olmesartan + Hydrochlorothiazide">
                    <activity>
                        <treatment>
                            <drugTreatment>
<flexibleDose minDose="20.0" maxDose="40.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Olmesartan"/>
                            </drugTreatment>
                            <drugTreatment>
<flexibleDose minDose="12.5" maxDose="25.0">
    <doseUnit scaleModifier="MILLI" perTime="P1D">
        <unit name="gram"/>
    </doseUnit>
</flexibleDose>
<drug name="Hydrochlorothiazide"/>
                            </drugTreatment>
                        </treatment>
                    </activity>
                    <usedBy epoch="Main phase" arm="Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD"/>
                    <notes/>
                </studyActivity>
            </activities>
            <notes>
                <note source="CLINICALTRIALS">NCT00846365</note>
                <note source="MANUAL">This is one of the "main studies" supporting the Edarbi application for monotherapy identified in the EMA EPAR available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002293/WC500119206.pdf

Retrieved from ClinicalTrials.gov using the Takeda internal study identifier 491-301.</note>
            </notes>
        </study>
    </studies>
    <metaAnalyses>
        <pairwiseMetaAnalysis name="Clinic SBP Azilsartan 40 vs 80">
            <indication name="Hypertensive disorder"/>
            <endpoint name="SBP mean trough (clinic, sitting)"/>
            <alternative>
                <treatmentDefinition>
                    <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Azilsartan Medoxomil 40 mg QD" study="TAK491-008 / NCT00696241"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD" study="TAK491-011 / NCT00591253"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD" study="TAK491-019 / NCT00696436"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD" study="TAK491-020 / NCT00760214"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Azilsartan Medoxomil 80 mg QD" study="TAK491-008 / NCT00696241"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD" study="TAK491-011 / NCT00591253"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD" study="TAK491-019 / NCT00696436"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD" study="TAK491-020 / NCT00760214"/>
                </arms>
            </alternative>
        </pairwiseMetaAnalysis>
        <networkMetaAnalysis name="Clinic SBP network">
            <indication name="Hypertensive disorder"/>
            <endpoint name="SBP mean trough (clinic, sitting)"/>
            <alternative>
                <treatmentDefinition>
                    <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Azilsartan Medoxomil 40 mg QD" study="TAK491-011 / NCT00591253"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD" study="TAK491-019 / NCT00696436"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD" study="TAK491-020 / NCT00760214"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Azilsartan Medoxomil 80 mg QD" study="TAK491-011 / NCT00591253"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD" study="TAK491-019 / NCT00696436"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD" study="TAK491-020 / NCT00760214"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <trivialCategory drug="Olmesartan"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Olmesartan 40 mg QD" study="TAK491-019 / NCT00696436"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <trivialCategory drug="Placebo"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Placebo QD" study="TAK491-011 / NCT00591253"/>
                    <arm name="Placebo QD" study="TAK491-019 / NCT00696436"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <trivialCategory drug="Ramipril"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Ramipril 10 mg QD" study="TAK491-020 / NCT00760214"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <trivialCategory drug="Valsartan"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Valsartan 320 mg QD" study="TAK491-019 / NCT00696436"/>
                </arms>
            </alternative>
            <consistencyResults>
                <mcmcSettings tuningIterations="20000" simulationIterations="50000" inferenceIterations="10000" thinningInterval="10" numberOfChains="4" varianceScalingFactor="2.5"/>
                <rankProbabilitySummary>0.0028 0.0012 0.0256 0.6165 0.3024 0.0515 0.0157 0.0145 0.0752 0.2997 0.4526 0.1423 0.0867 0.0691 0.2247 0.0607 0.1253 0.4335 0.2022 0.1779 0.3426 0.0167 0.0616 0.199 0.3912 0.3337 0.1487 0.005 0.0321 0.0893 0.3014 0.4036 0.1832 0.0014 0.026 0.0844</rankProbabilitySummary>
                <relativeEffectsSummary>
                    <means>-0.40107714771571407 1.8699012455537143 10.531855151210141 8.391530330317707 3.753727471678825</means>
                    <covariance>13.391733131284523 7.355350166620962 6.562345808005968 6.7752595029177645 6.558490194255779 31.96293835739325 9.042919199218812 3.4970174423654323 12.313888465756271 18.502282350946633 3.46080019808027 7.9508766407779925 33.33558739136859 2.924608921715573 31.033228426769085</covariance>
                </relativeEffectsSummary>
                <relativeEffectsQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-8.239071979723496"/>
                        <quantile level="0.5" value="-0.4084851466178875"/>
                        <quantile level="0.975" value="7.454782319634181"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-10.469711420027485"/>
                        <quantile level="0.5" value="1.898303470143608"/>
                        <quantile level="0.975" value="13.892371350869542"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="1.5384562347073887"/>
                        <quantile level="0.5" value="10.598027537441363"/>
                        <quantile level="0.975" value="19.58656344980336"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-4.086851065315675"/>
                        <quantile level="0.5" value="8.438926847611832"/>
                        <quantile level="0.975" value="20.16181085900899"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-8.266139196452885"/>
                        <quantile level="0.5" value="3.8100614098972847"/>
                        <quantile level="0.975" value="15.306097220590024"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-7.454782319634176"/>
                        <quantile level="0.5" value="0.4084851466178875"/>
                        <quantile level="0.975" value="8.239071979723498"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-9.635382533755264"/>
                        <quantile level="0.5" value="2.3056630575010337"/>
                        <quantile level="0.975" value="13.841500250555645"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="1.49006227183968"/>
                        <quantile level="0.5" value="10.979551399411893"/>
                        <quantile level="0.975" value="20.103834636744462"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-3.8999042835897773"/>
                        <quantile level="0.5" value="8.87629268259649"/>
                        <quantile level="0.975" value="20.781674172642674"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-7.6566131739202445"/>
                        <quantile level="0.5" value="4.182161201922916"/>
                        <quantile level="0.975" value="16.169362997518817"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-13.892371350869533"/>
                        <quantile level="0.5" value="-1.898303470143608"/>
                        <quantile level="0.975" value="10.469711420027487"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-13.841500250555635"/>
                        <quantile level="0.5" value="-2.3056630575010337"/>
                        <quantile level="0.975" value="9.635382533755267"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-3.0879470224208148"/>
                        <quantile level="0.5" value="8.681146995646788"/>
                        <quantile level="0.975" value="20.6299454738262"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-9.68000859023491"/>
                        <quantile level="0.5" value="6.592833959875414"/>
                        <quantile level="0.975" value="22.549400128259634"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-11.414962804101336"/>
                        <quantile level="0.5" value="1.8590896127760161"/>
                        <quantile level="0.975" value="15.250199906404077"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-19.58656344980336"/>
                        <quantile level="0.5" value="-10.598027537441363"/>
                        <quantile level="0.975" value="-1.5384562347073856"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-20.103834636744455"/>
                        <quantile level="0.5" value="-10.979551399411893"/>
                        <quantile level="0.975" value="-1.4900622718396632"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-20.629945473826158"/>
                        <quantile level="0.5" value="-8.681146995646788"/>
                        <quantile level="0.975" value="3.0879470224208188"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-16.461369848448648"/>
                        <quantile level="0.5" value="-2.156101340008691"/>
                        <quantile level="0.975" value="12.09165395496556"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-19.283790306459764"/>
                        <quantile level="0.5" value="-6.731282224808771"/>
                        <quantile level="0.975" value="5.4166587950267795"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-20.161810859008988"/>
                        <quantile level="0.5" value="-8.438926847611832"/>
                        <quantile level="0.975" value="4.086851065315676"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-20.781674172642663"/>
                        <quantile level="0.5" value="-8.87629268259649"/>
                        <quantile level="0.975" value="3.8999042835897817"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-22.549400128259627"/>
                        <quantile level="0.5" value="-6.592833959875414"/>
                        <quantile level="0.975" value="9.68000859023492"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-12.09165395496555"/>
                        <quantile level="0.5" value="2.156101340008691"/>
                        <quantile level="0.975" value="16.46136984844866"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-20.781461708730657"/>
                        <quantile level="0.5" value="-4.73092018298001"/>
                        <quantile level="0.975" value="11.289076954256675"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-15.306097220590022"/>
                        <quantile level="0.5" value="-3.8100614098972847"/>
                        <quantile level="0.975" value="8.266139196452892"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-16.169362997518803"/>
                        <quantile level="0.5" value="-4.182161201922916"/>
                        <quantile level="0.975" value="7.65661317392025"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-15.250199906404072"/>
                        <quantile level="0.5" value="-1.8590896127760161"/>
                        <quantile level="0.975" value="11.414962804101338"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-5.416658795026772"/>
                        <quantile level="0.5" value="6.731282224808771"/>
                        <quantile level="0.975" value="19.283790306459764"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-11.28907695425667"/>
                        <quantile level="0.5" value="4.73092018298001"/>
                        <quantile level="0.975" value="20.78146170873066"/>
                    </relativeEffectQuantileSummary>
                </relativeEffectsQuantileSummary>
                <summary psrf="1.000447950147578">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-8.239071979723496"/>
                    <quantile level="0.5" value="-0.4084851466178875"/>
                    <quantile level="0.975" value="7.454782319634181"/>
                </summary>
                <summary psrf="1.0007223198670796">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <trivialCategory drug="Olmesartan"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-10.469711420027485"/>
                    <quantile level="0.5" value="1.898303470143608"/>
                    <quantile level="0.975" value="13.892371350869542"/>
                </summary>
                <summary psrf="1.0004821044419903">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <trivialCategory drug="Placebo"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="1.5384562347073887"/>
                    <quantile level="0.5" value="10.598027537441363"/>
                    <quantile level="0.975" value="19.58656344980336"/>
                </summary>
                <summary psrf="1.0002948771076852">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <trivialCategory drug="Ramipril"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-4.086851065315675"/>
                    <quantile level="0.5" value="8.438926847611832"/>
                    <quantile level="0.975" value="20.16181085900899"/>
                </summary>
                <summary psrf="1.0005162960404899">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <trivialCategory drug="Valsartan"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-8.266139196452885"/>
                    <quantile level="0.5" value="3.8100614098972847"/>
                    <quantile level="0.975" value="15.306097220590024"/>
                </summary>
                <summary psrf="1.0042633103312752">
                    <variance name="var.d"/>
                    <quantile level="0.025" value="1.1018004126196412"/>
                    <quantile level="0.5" value="4.650269921794505"/>
                    <quantile level="0.975" value="13.099022343340964"/>
                </summary>
            </consistencyResults>
        </networkMetaAnalysis>
        <networkMetaAnalysis name="Non-SAE network">
            <indication name="Hypertensive disorder"/>
            <adverseEvent name="Non-SAE"/>
            <alternative>
                <treatmentDefinition>
                    <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Azilsartan Medoxomil 40 mg QD" study="TAK491-011 / NCT00591253"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD" study="TAK491-019 / NCT00696436"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD" study="TAK491-020 / NCT00760214"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Azilsartan Medoxomil 80 mg QD" study="TAK491-011 / NCT00591253"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD" study="TAK491-019 / NCT00696436"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD" study="TAK491-020 / NCT00760214"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <trivialCategory drug="Olmesartan"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Olmesartan 40 mg QD" study="TAK491-019 / NCT00696436"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <trivialCategory drug="Placebo"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Placebo QD" study="TAK491-011 / NCT00591253"/>
                    <arm name="Placebo QD" study="TAK491-019 / NCT00696436"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <trivialCategory drug="Ramipril"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Ramipril 10 mg QD" study="TAK491-020 / NCT00760214"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <trivialCategory drug="Valsartan"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Valsartan 320 mg QD" study="TAK491-019 / NCT00696436"/>
                </arms>
            </alternative>
            <consistencyResults>
                <mcmcSettings tuningIterations="20000" simulationIterations="50000" inferenceIterations="10000" thinningInterval="10" numberOfChains="4" varianceScalingFactor="2.5"/>
                <rankProbabilitySummary>0.0317 0.0124 0.1566 0.0455 0.6155 0.1383 0.1473 0.0645 0.2868 0.1188 0.1631 0.2195 0.2272 0.1248 0.1751 0.1706 0.0893 0.213 0.2731 0.1798 0.145 0.1872 0.0555 0.1594 0.2097 0.2952 0.1195 0.2007 0.0408 0.1341 0.111 0.3233 0.117 0.2772 0.0358 0.1357</rankProbabilitySummary>
                <relativeEffectsSummary>
                    <means>-0.18301964162489118 0.15827249711030675 -0.1057502106657408 0.6169876349533246 0.11354405132528748</means>
                    <covariance>0.17886739163178256 0.08848112338746907 0.0855097376565341 0.08967677458841863 0.0883644953808641 0.37486075171417765 0.1153021342187062 0.046420278051805784 0.15500778373774526 0.2713021714957754 0.04367346863029157 0.12280749257713376 0.3893661763024843 0.04723956877065086 0.3851452077439822</covariance>
                </relativeEffectsSummary>
                <relativeEffectsQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.0397133902801252"/>
                        <quantile level="0.5" value="-0.20782868583165875"/>
                        <quantile level="0.975" value="0.7291168896954063"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.1305194637604734"/>
                        <quantile level="0.5" value="0.16734136068284902"/>
                        <quantile level="0.975" value="1.3916144953771024"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.1819214973431058"/>
                        <quantile level="0.5" value="-0.10455431688062639"/>
                        <quantile level="0.975" value="0.9236613802122974"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-0.6717870539739821"/>
                        <quantile level="0.5" value="0.5917712337083987"/>
                        <quantile level="0.975" value="1.9142947239702215"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.1748418272588008"/>
                        <quantile level="0.5" value="0.08552218124481746"/>
                        <quantile level="0.975" value="1.4175055453679857"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-0.7291168896954058"/>
                        <quantile level="0.5" value="0.20782868583165875"/>
                        <quantile level="0.975" value="1.0397133902801254"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-0.9494062429812183"/>
                        <quantile level="0.5" value="0.35857688266757104"/>
                        <quantile level="0.975" value="1.6030704024584046"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.06570801159078"/>
                        <quantile level="0.5" value="0.0814007138573472"/>
                        <quantile level="0.975" value="1.0768553473429483"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-0.5259365137333414"/>
                        <quantile level="0.5" value="0.7755226644307163"/>
                        <quantile level="0.975" value="2.089576047208612"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.029131604215277"/>
                        <quantile level="0.5" value="0.3131292007885631"/>
                        <quantile level="0.975" value="1.5613406475303246"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.3916144953771015"/>
                        <quantile level="0.5" value="-0.16734136068284902"/>
                        <quantile level="0.975" value="1.1305194637604736"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.6030704024584044"/>
                        <quantile level="0.5" value="-0.35857688266757104"/>
                        <quantile level="0.975" value="0.9494062429812185"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.6076646415170743"/>
                        <quantile level="0.5" value="-0.2726256816476022"/>
                        <quantile level="0.975" value="1.0553241098494355"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.223378019461727"/>
                        <quantile level="0.5" value="0.4324205664158576"/>
                        <quantile level="0.975" value="2.1678167382199507"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.4031849560069485"/>
                        <quantile level="0.5" value="-0.07156787252680133"/>
                        <quantile level="0.975" value="1.3680165511094975"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-0.9236613802122967"/>
                        <quantile level="0.5" value="0.10455431688062639"/>
                        <quantile level="0.975" value="1.1819214973431065"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.0768553473429479"/>
                        <quantile level="0.5" value="-0.0814007138573472"/>
                        <quantile level="0.975" value="1.0657080115907802"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.0553241098494346"/>
                        <quantile level="0.5" value="0.2726256816476022"/>
                        <quantile level="0.975" value="1.6076646415170748"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-0.8187880041034773"/>
                        <quantile level="0.5" value="0.7302128900683145"/>
                        <quantile level="0.975" value="2.306493491691938"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.0914083101627874"/>
                        <quantile level="0.5" value="0.224338818426573"/>
                        <quantile level="0.975" value="1.5695667745653887"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.9142947239702206"/>
                        <quantile level="0.5" value="-0.5917712337083987"/>
                        <quantile level="0.975" value="0.6717870539739828"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.089576047208612"/>
                        <quantile level="0.5" value="-0.7755226644307163"/>
                        <quantile level="0.975" value="0.5259365137333419"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.1678167382199485"/>
                        <quantile level="0.5" value="-0.4324205664158576"/>
                        <quantile level="0.975" value="1.2233780194617274"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.306493491691938"/>
                        <quantile level="0.5" value="-0.7302128900683145"/>
                        <quantile level="0.975" value="0.8187880041034779"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.2212407339156246"/>
                        <quantile level="0.5" value="-0.4700218253925647"/>
                        <quantile level="0.975" value="1.2313019164535748"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.417505545367985"/>
                        <quantile level="0.5" value="-0.08552218124481746"/>
                        <quantile level="0.975" value="1.1748418272588008"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.5613406475303242"/>
                        <quantile level="0.5" value="-0.3131292007885631"/>
                        <quantile level="0.975" value="1.0291316042152774"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.3680165511094968"/>
                        <quantile level="0.5" value="0.07156787252680133"/>
                        <quantile level="0.975" value="1.4031849560069494"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.5695667745653878"/>
                        <quantile level="0.5" value="-0.224338818426573"/>
                        <quantile level="0.975" value="1.0914083101627883"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.2313019164535746"/>
                        <quantile level="0.5" value="0.4700218253925647"/>
                        <quantile level="0.975" value="2.221240733915625"/>
                    </relativeEffectQuantileSummary>
                </relativeEffectsQuantileSummary>
                <summary psrf="1.0013476205513099">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-1.0397133902801252"/>
                    <quantile level="0.5" value="-0.20782868583165875"/>
                    <quantile level="0.975" value="0.7291168896954063"/>
                </summary>
                <summary psrf="1.002473266309507">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <trivialCategory drug="Olmesartan"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-1.1305194637604734"/>
                    <quantile level="0.5" value="0.16734136068284902"/>
                    <quantile level="0.975" value="1.3916144953771024"/>
                </summary>
                <summary psrf="1.001978993276741">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <trivialCategory drug="Placebo"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-1.1819214973431058"/>
                    <quantile level="0.5" value="-0.10455431688062639"/>
                    <quantile level="0.975" value="0.9236613802122974"/>
                </summary>
                <summary psrf="1.0021794169854572">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <trivialCategory drug="Ramipril"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-0.6717870539739821"/>
                    <quantile level="0.5" value="0.5917712337083987"/>
                    <quantile level="0.975" value="1.9142947239702215"/>
                </summary>
                <summary psrf="1.0015998170855005">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <trivialCategory drug="Valsartan"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-1.1748418272588008"/>
                    <quantile level="0.5" value="0.08552218124481746"/>
                    <quantile level="0.975" value="1.4175055453679857"/>
                </summary>
                <summary psrf="1.028341700112303">
                    <variance name="var.d"/>
                    <quantile level="0.025" value="0.004771009609496771"/>
                    <quantile level="0.5" value="0.5427867061843015"/>
                    <quantile level="0.975" value="1.0171687718361646"/>
                </summary>
            </consistencyResults>
        </networkMetaAnalysis>
        <networkMetaAnalysis name="SAE network">
            <indication name="Hypertensive disorder"/>
            <adverseEvent name="SAE"/>
            <alternative>
                <treatmentDefinition>
                    <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Azilsartan Medoxomil 40 mg QD" study="TAK491-011 / NCT00591253"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD" study="TAK491-019 / NCT00696436"/>
                    <arm name="Azilsartan Medoxomil 40 mg QD" study="TAK491-020 / NCT00760214"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Azilsartan Medoxomil 80 mg QD" study="TAK491-011 / NCT00591253"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD" study="TAK491-019 / NCT00696436"/>
                    <arm name="Azilsartan Medoxomil 80 mg QD" study="TAK491-020 / NCT00760214"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <trivialCategory drug="Olmesartan"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Olmesartan 40 mg QD" study="TAK491-019 / NCT00696436"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <trivialCategory drug="Placebo"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Placebo QD" study="TAK491-011 / NCT00591253"/>
                    <arm name="Placebo QD" study="TAK491-019 / NCT00696436"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <trivialCategory drug="Ramipril"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Ramipril 10 mg QD" study="TAK491-020 / NCT00760214"/>
                </arms>
            </alternative>
            <alternative>
                <treatmentDefinition>
                    <trivialCategory drug="Valsartan"/>
                </treatmentDefinition>
                <arms>
                    <arm name="Valsartan 320 mg QD" study="TAK491-019 / NCT00696436"/>
                </arms>
            </alternative>
            <consistencyResults>
                <mcmcSettings tuningIterations="20000" simulationIterations="50000" inferenceIterations="10000" thinningInterval="10" numberOfChains="4" varianceScalingFactor="2.5"/>
                <rankProbabilitySummary>0.1213 0.1444 0.3533 0.069 0.0974 0.2146 0.1959 0.2634 0.1872 0.0964 0.0899 0.1672 0.2283 0.2507 0.129 0.1089 0.139 0.1441 0.2524 0.1978 0.135 0.1292 0.1434 0.1422 0.1542 0.1103 0.1107 0.1994 0.2349 0.1905 0.0479 0.0334 0.0848 0.3971 0.2954 0.1414</rankProbabilitySummary>
                <relativeEffectsSummary>
                    <means>0.057143079477014844 0.2355143947262469 -0.7768778587757877 -0.4919401663616148 -0.06642943634744153</means>
                    <covariance>0.6122558449068254 0.3383314074701542 0.32520152820456744 0.3108570504372709 0.33338126402666995 1.440557440600469 0.4610798712351451 0.18136672289874609 0.6102441433760667 1.5751680884601909 0.16776099900291858 0.508242122164469 1.2247377202363088 0.16440961760153078 1.5251375037388522</covariance>
                </relativeEffectsSummary>
                <relativeEffectsQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.6773854038599225"/>
                        <quantile level="0.5" value="0.12449462539219497"/>
                        <quantile level="0.975" value="1.5479166377623987"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.2885101106027905"/>
                        <quantile level="0.5" value="0.33808366337705853"/>
                        <quantile level="0.975" value="2.5993871101029122"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-3.480435233685736"/>
                        <quantile level="0.5" value="-0.7097007287144933"/>
                        <quantile level="0.975" value="1.4822727068902992"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.9005661282559783"/>
                        <quantile level="0.5" value="-0.4366669200216274"/>
                        <quantile level="0.975" value="1.697364757047175"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.722636780641885"/>
                        <quantile level="0.5" value="-0.04468000747837103"/>
                        <quantile level="0.975" value="2.3245977959144963"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.5479166377623987"/>
                        <quantile level="0.5" value="-0.12449462539219497"/>
                        <quantile level="0.975" value="1.6773854038599236"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.2572422678996067"/>
                        <quantile level="0.5" value="0.2080520451781574"/>
                        <quantile level="0.975" value="2.6037502853628594"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-3.515326371139698"/>
                        <quantile level="0.5" value="-0.7772674234386117"/>
                        <quantile level="0.975" value="1.4647471678837254"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.8520542963038142"/>
                        <quantile level="0.5" value="-0.542628269080824"/>
                        <quantile level="0.975" value="1.7689550920560047"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.593333190454955"/>
                        <quantile level="0.5" value="-0.1483396982490619"/>
                        <quantile level="0.975" value="2.370643480194329"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.5993871101029113"/>
                        <quantile level="0.5" value="-0.33808366337705853"/>
                        <quantile level="0.975" value="2.2885101106027914"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.6037502853628594"/>
                        <quantile level="0.5" value="-0.2080520451781574"/>
                        <quantile level="0.975" value="2.257242267899607"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-4.030933788456664"/>
                        <quantile level="0.5" value="-0.9802816005232438"/>
                        <quantile level="0.975" value="1.7474813331595538"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-3.8760408475385497"/>
                        <quantile level="0.5" value="-0.7135247809533487"/>
                        <quantile level="0.975" value="2.4811060658049926"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-3.0362887174437194"/>
                        <quantile level="0.5" value="-0.2979838424573896"/>
                        <quantile level="0.975" value="2.3214659634156143"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.482272706890298"/>
                        <quantile level="0.5" value="0.7097007287144933"/>
                        <quantile level="0.975" value="3.4804352336857374"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.4647471678837238"/>
                        <quantile level="0.5" value="0.7772674234386117"/>
                        <quantile level="0.975" value="3.5153263711397003"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.747481333159553"/>
                        <quantile level="0.5" value="0.9802816005232438"/>
                        <quantile level="0.975" value="4.0309337884566645"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.666778419064842"/>
                        <quantile level="0.5" value="0.18800650509641292"/>
                        <quantile level="0.975" value="3.5803648821791265"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.122975660869639"/>
                        <quantile level="0.5" value="0.7048171197048364"/>
                        <quantile level="0.975" value="3.663420802271411"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.697364757047175"/>
                        <quantile level="0.5" value="0.4366669200216274"/>
                        <quantile level="0.975" value="2.9005661282559783"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-1.7689550920560033"/>
                        <quantile level="0.5" value="0.542628269080824"/>
                        <quantile level="0.975" value="2.8520542963038165"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.481106065804987"/>
                        <quantile level="0.5" value="0.7135247809533487"/>
                        <quantile level="0.975" value="3.876040847538551"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-3.5803648821791256"/>
                        <quantile level="0.5" value="-0.18800650509641292"/>
                        <quantile level="0.975" value="2.666778419064844"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.7798525022250296"/>
                        <quantile level="0.5" value="0.457607231145245"/>
                        <quantile level="0.975" value="3.5725830924135025"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.3245977959144954"/>
                        <quantile level="0.5" value="0.04468000747837103"/>
                        <quantile level="0.975" value="2.7226367806418854"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.3706434801943277"/>
                        <quantile level="0.5" value="0.1483396982490619"/>
                        <quantile level="0.975" value="2.5933331904549557"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Olmesartan"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-2.321465963415614"/>
                        <quantile level="0.5" value="0.2979838424573896"/>
                        <quantile level="0.975" value="3.0362887174437203"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Placebo"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-3.663420802271409"/>
                        <quantile level="0.5" value="-0.7048171197048364"/>
                        <quantile level="0.975" value="2.1229756608696393"/>
                    </relativeEffectQuantileSummary>
                    <relativeEffectQuantileSummary>
                        <relativeEffect whichEvidence="ALL">
                            <treatmentDefinition>
<trivialCategory drug="Valsartan"/>
                            </treatmentDefinition>
                            <treatmentDefinition>
<trivialCategory drug="Ramipril"/>
                            </treatmentDefinition>
                        </relativeEffect>
                        <quantile level="0.025" value="-3.5725830924135"/>
                        <quantile level="0.5" value="-0.457607231145245"/>
                        <quantile level="0.975" value="2.7798525022250304"/>
                    </relativeEffectQuantileSummary>
                </relativeEffectsQuantileSummary>
                <summary psrf="1.0029721335011492">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-1.6773854038599225"/>
                    <quantile level="0.5" value="0.12449462539219497"/>
                    <quantile level="0.975" value="1.5479166377623987"/>
                </summary>
                <summary psrf="1.0020188193768014">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <trivialCategory drug="Olmesartan"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-2.2885101106027905"/>
                    <quantile level="0.5" value="0.33808366337705853"/>
                    <quantile level="0.975" value="2.5993871101029122"/>
                </summary>
                <summary psrf="1.0037520307713845">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <trivialCategory drug="Placebo"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-3.480435233685736"/>
                    <quantile level="0.5" value="-0.7097007287144933"/>
                    <quantile level="0.975" value="1.4822727068902992"/>
                </summary>
                <summary psrf="1.0009871585399912">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <trivialCategory drug="Ramipril"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-2.9005661282559783"/>
                    <quantile level="0.5" value="-0.4366669200216274"/>
                    <quantile level="0.975" value="1.697364757047175"/>
                </summary>
                <summary psrf="1.0027464322734334">
                    <relativeEffect whichEvidence="ALL">
                        <treatmentDefinition>
                            <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                        </treatmentDefinition>
                        <treatmentDefinition>
                            <trivialCategory drug="Valsartan"/>
                        </treatmentDefinition>
                    </relativeEffect>
                    <quantile level="0.025" value="-2.722636780641885"/>
                    <quantile level="0.5" value="-0.04468000747837103"/>
                    <quantile level="0.975" value="2.3245977959144963"/>
                </summary>
                <summary psrf="1.007354616819356">
                    <variance name="var.d"/>
                    <quantile level="0.025" value="0.02581688241341515"/>
                    <quantile level="0.5" value="0.8563533232720038"/>
                    <quantile level="0.975" value="1.9092246746493862"/>
                </summary>
            </consistencyResults>
        </networkMetaAnalysis>
    </metaAnalyses>
    <benefitRiskAnalyses>
        <metaBenefitRiskAnalysis name="Benefit-risk" analysisType="SMAA">
            <indication name="Hypertensive disorder"/>
            <baseline>
                <treatmentDefinition>
                    <trivialCategory drug="Placebo"/>
                </treatmentDefinition>
            </baseline>
            <alternatives>
                <treatmentDefinition>
                    <richCategory categoryName="40" drug="Azilsartan" name="20/40/80"/>
                </treatmentDefinition>
                <treatmentDefinition>
                    <richCategory categoryName="80" drug="Azilsartan" name="20/40/80"/>
                </treatmentDefinition>
                <treatmentDefinition>
                    <trivialCategory drug="Olmesartan"/>
                </treatmentDefinition>
                <treatmentDefinition>
                    <trivialCategory drug="Placebo"/>
                </treatmentDefinition>
                <treatmentDefinition>
                    <trivialCategory drug="Ramipril"/>
                </treatmentDefinition>
                <treatmentDefinition>
                    <trivialCategory drug="Valsartan"/>
                </treatmentDefinition>
            </alternatives>
            <metaAnalyses>
                <metaAnalysis name="Clinic SBP network"/>
                <metaAnalysis name="Non-SAE network"/>
                <metaAnalysis name="SAE network"/>
            </metaAnalyses>
            <decisionContext>
                <therapeuticContext></therapeuticContext>
                <comparator></comparator>
                <timeHorizon></timeHorizon>
                <stakeholderPerspective></stakeholderPerspective>
            </decisionContext>
        </metaBenefitRiskAnalysis>
    </benefitRiskAnalyses>
</addis-data>
